VerifyMe (VRME) 10-K 16 Apr 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Apr. 15, 2015	Apr. 10, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	LLTI
Entity Registrant Name	LASERLOCK TECHNOLOGIES INC
Entity Central Index Key	1104038
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		307,578,149
Entity Public Float			$1,843,020

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
CURRENT ASSETS
Cash and cash equivalents	$63,956	$1,285,973
Accounts receivable, net of allowance of $0 at December 31, 2014 and 2013		3,573
Inventory	97,360	34,271
Prepaid expenses	181,086	189,474
TOTAL CURRENT ASSETS	342,402	1,513,291
PROPERTY AND EQUIPMENT
Capital equipment, net of accumulated depreciation of $161,205 and $91,952 as of December 31, 2014 and 2013	74,821	144,074
OTHER ASSETS
Deposits	37,197	37,197
Patents and Trademark, net of accumulated amortization of $118,502 and $105,393 as of December 31, 2014 and 2013	107,586	120,695
TOTAL OTHER ASSETS	144,783	157,892
TOTAL ASSETS	562,006	1,815,257
CURRENT LIABILITIES
Accounts payable and accrued expenses	5,217,770	316,785
Accrued interest - related parties	43,215	16,667
Deferred revenue	16,667
Embedded derivative liability		800,000
Senior convertible notes payable - related parties	114,000
Notes payable	812,553	50,000
TOTAL CURRENT LIABILITIES	6,204,205	1,183,452
LONG-TERM LIABILITIES
Warrant liability	6,370,709	6,000,000
Accrued interest - related parties	112,885	300,677
Senior secured convertible notes payable - related parties		330,249
TOTAL LONG-TERM LIABILITIES	6,483,594	6,630,926
TOTAL LIABILITIES	12,712,799	7,814,378
CONTINGENCIES
STOCKHOLDERS' DEFICIT
Convertible Preferred Stock, $ .001 par value; 75,000,000 shares authorized; 21,111,111 shares issued and outstanding as of December 31, 2014 and 2013	633,333	633,333
Common stock, $ .001 par value; 675,000,000 shares authorized; 337,374,052 shares issued and 307,578,149 outstanding at December 31, 2014 and 319,862,042 shares issued and 290,066,139 outstanding at December 31, 2013	337,374	319,862
Additional paid in capital	24,713,294	22,938,983
Treasury stock, at cost (29,795,903 shares at December 31, 2014 and 2013)	-113,389	-113,389
Accumulated deficit	-37,696,405	-29,777,910
STOCKHOLDERS' DEFICIT	-12,125,793	-5,999,121
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$562,006	$1,815,257

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Allowance for accounts receivable (in dollars)	$0	$0
Accumulated depreciation on capital equipment (in dollars)	161,205	91,952
Accumulated amortization, patent and trademarks (in dollars)	$118,502	$105,393
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	75,000,000	75,000,000
Preferred stock, shares issued	21,111,111	21,111,111
Preferred stock, shares outstanding	21,111,111	21,111,111
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	675,000,000	675,000,000
Common stock, shares issued	337,374,052	319,862,042
Common stock, shares outstanding	307,578,149	290,066,139
Treasury stock, shares	29,795,903	29,795,903

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
NET REVENUE
Sales	$116,265		$3,140
Royalties	8,333
TOTAL NET REVENUE	124,598		3,140
COST OF SALES	113,024		2,710
GROSS PROFIT	11,574		430
OPERATING EXPENSES
General and administrative	811,916		762,668
Legal and accounting	344,903		475,948
Payroll expenses	1,611,376	[1]	9,485,339	[1]
Research and development	10,590,271		655,840
Sales and marketing	218,443		261,804
Total operating expenses	13,576,909		11,641,599
(LOSS) BEFORE OTHER INCOME	-13,565,335		-11,641,169
OTHER INCOME (EXPENSE)
Interest income	0		0
Interest expense	-199,364		-127,825
Loss on extinguishment of debt	-82,000		-1,221,875
Change in fair value of warrants	5,128,204		-604,209
Change in fair value of embedded derivative liability	800,000		200,000
Fair value of warrants in excess of consideration for convertible preferred stock			-2,995,791
TOTAL OTHER INCOME (EXPENSE)	5,646,840		-4,749,700
LOSS BEFORE INCOME TAX BENEFIT	-7,918,495		-16,390,869
INCOME TAX BENEFIT	0		0
NET LOSS	-7,918,495		-16,390,869
Less: Deemed dividend distribution			-1,000,000
NET LOSS APPLICABLE TO COMMON STOCKHOLDERS	($7,918,495)		($17,390,869)
BASIC (in dollars per share)	($0.03)		($0.07)
DILUTED (in dollars per share)	($0.03)		($0.07)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
BASIC (in shares)	303,748,409		250,043,403
DILUTED (in shares)	303,748,409		250,043,403
[1]	- includes share based compensation of $860,235 for the year ended December 31, 2014 and $8,619,137 for the year ended December 31, 2013

Statements_of_Operations_Paren

Statements of Operations (Parenthetical) (Payroll expenses, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Payroll expenses
Share based compensation	$860,235	$8,619,137

Statement_of_Changes_in_Stockh

Statement of Changes in Stockholders' Equity (Deficit) (USD $)	Total	Warrant Group One	Warrant Group Two	Convertible Preferred Stock	Common Stock	Common Stock	Common Stock	Additional Paid-In Capital	Additional Paid-In Capital	Additional Paid-In Capital	Treasury Stock	Deficit Accumulated During the Development Stage
						Warrant Group One	Warrant Group Two		Warrant Group One	Warrant Group Two
Balance at Dec. 31, 2012	($1,864,257)				$248,244			$11,387,929			($113,389)	($13,387,041)
Balance (in shares) at Dec. 31, 2012					218,448,109
Issuance of shares for services	1,000,000			1,000,000
Issuance of shares for services (in shares)				33,333,333
Conversion of shares of preferred stock to common stock				-366,667	12,222			354,445
Conversion of shares of preferred stock to common stock ( in shares)				-12,222,222	12,222,222
Issuance of shares of common stock	235,000				4,811			230,189
Fair value of employee stock options	8,619,136							8,619,136
Issuance of shares of common stock ( in shares)					4,811,111
Shares issued for conversion of notes payable and accrued interest	1,890,000				18,275			1,871,725
Shares issued for conversion of notes payable and accrued interest ( in shares)					18,275,000
Exercise of options	17,919				3,335			14,584
Exercise of options ( in shares)					3,335,000
Exercise of warrants		10,000	59,999			1,000	6,000		9,000	53,999
Exercise of warrants (in shares)						1,000,000	6,000,000
Stockholders' Equity, Other	1,423,951				25,975			1,397,976
Stockholders' Equity, Other ( in shares)					25,974,697
Net loss	-16,390,869											-16,390,869
Deemed dividend distribution	-1,000,000							-1,000,000
Balance at Dec. 31, 2013	-5,999,121			633,333	319,862			22,938,983			-113,389	-29,777,910
Balance (in shares) at Dec. 31, 2013				21,111,111	290,066,139
Balance at Sep. 30, 2013
Shares issued for conversion of notes payable and accrued interest					25,974,697
Balance at Dec. 31, 2013	-5,999,121				319,862			22,938,983			-113,389	-29,777,910
Balance (in shares) at Dec. 31, 2013					290,066,139
Issuance of shares for services	400,000				6,349			393,651
Issuance of shares for services (in shares)					6,349,206
Cashless exercise of options	0				2,714			-2,714
Cashless exercise of options (in shares)					2,714,285
Fair value of employee stock options	860,235							860,235
Issuance of shares of common stock for settlement of debt	506,588				8,449			498,139
Issuance of shares of common stock for settlement of debt (in shares)					8,448,519
Forgiveness of related party debt	25,000							25,000
Net loss	-7,918,495											-7,918,495
Balance at Dec. 31, 2014	($12,125,793)			$633,333	$337,374			$24,713,294			($113,389)	($37,696,405)
Balance (in shares) at Dec. 31, 2014				21,111,111	307,578,149

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	($7,918,495)	($16,390,869)
Adjustments to reconcile net loss to net cash used in operating activities
Fair value of options issued in exchange for services	860,235	8,619,137
Accretion of discount on notes payable	202,377	3,718
Change in fair value warrant liability	-5,128,204	604,209
Change in fair value of embedded derivative liability	-800,000	-200,000
Fair value of warrants in excess of consideration for convertible preferred stock		2,995,791
Fair value of stock in excess of converted notes payable and accrued interest	82,000	1,221,875
Amortization and depreciation	82,362	81,929
Stock and warrants issued in exchange for technology	5,736,089
(Increase) decrease in assets
Accounts receivable	3,573	-100
Inventory	-63,089	-14,291
Prepaid expenses	8,388	560,526
Deposits		-37,197
Increase (decrease) in liabilities
Accounts payable and accrued expenses	4,898,080	-233,497
Deferred revenue	16,667
Net cash used in operating activities	-2,020,017	-2,788,769
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		-10,573
Purchase of intangibles		-21,954
Net cash used in investing activities		-32,527
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of preferred stock		1,000,000
Proceeds from issuance of common stock		235,000
Proceeds from exercise of stock options		17,919
Proceeds from exercise of warrants		10,000
Proceeds from issuance of notes payable	798,000
Repayments of notes payable		-150,000
Net cash provided by financing activities	798,000	1,112,919
NET DECREASE IN CASH AND CASH EQUIVALENTS	-1,222,017	-1,708,377
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR	1,285,973	2,994,350
CASH AND CASH EQUIVALENTS - END OF YEAR	63,956	1,285,973
Cash paid during the year for:
Interest		13,895
Income taxes	0	0
Fair value of stock issued for conversion of notes payable and accrued interest	506,588	2,092,075
Fair value of stock issued for conversion of preferred stock to common stock		366,667
Accretion of discount on preferred stock as deemed dividend distribution		1,000,000
Fair value of beneficial conversion feature		1,500,000
Conversion of warrant in lieu of cash repayment of notes payable		60,000
Fair value of warrants issued as debt discount	211,576
Forgiveness of related party debt	$25,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Nature of the Business
	LaserLock Technologies, Inc. (the “Company”) was incorporated in the State of Nevada on November 10, 1999. The Company is based in Washington, D.C. and its common stock is traded on the OTCQB under the ticker symbol “LLTI”. A high-tech solutions company in the field of authenticating people and products, LaserLock offers state-of-the-art solutions to combat identity fraud and counterfeiting utilizing multi-factor authentication and a suite of security pigments for governments, health care providers, the gaming industry, the financial services industry and high-end retailers.
	The Company invests in developing new proprietary color shifting inks that it believes will allow it to penetrate broader markets and result in increased revenues. The Company refines its technologies and their applications, and now has what it believes to be one of the most cost effective and efficient authentication technologies available. Its most recent technology takes advantage of the new ubiquitous energy efficient fluorescent lighting to change the color of ink, resulting in numerous potential new applications ranging from credit cards to drivers licenses, passports, stock certificates, clothing labels, currency, ID cards, and tax stamps. The technologies can also be used to protect DVDs, apparel, pharmaceuticals, and virtually any other physical product.
	The Company’s digital solution is a multi-platform (iOS and Android) strong authentication solution that integrates biometrics and geo-location tagging. The solution completely eliminates passwords and the inherently weak security they provide. The solution also removes the user complexity associated with having to manage many complex passwords. The solution can be delivered either as a high availability cloud service, managed by the Company, or as licensed software product for operation on the client’s premises.
	The solution integrates three independent authentication factors – something you have (for instance a smartphone), something you know (for instance a color gesture swipe) and something you are (for instance your facial geometry)—into a simple, fast, intuitive solution. The system can also accurately determine the precise location of the individual using a variety of mechanisms including GPS, cell tower triangulation, IP or WIFI address. Because the solution incorporates biometrics it completely eliminates the possibility that users might share their authentication credentials. The combination of biometrics and geolocation provides extremely strong transactional evidence, making it nearly impossible for an end-user to refute having been part of a transaction.
	The Company’s activities are subject to significant risks and uncertainties, including the need to secure additional funding to operationalize the Company’s current technology.
	Basis of Presentation
	The accompanying financial statements are presented in accordance with accounting principles generally accepted in the United States of America.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
	Comprehensive Income
	The Company follows Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 220 in reporting comprehensive income. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income (loss), comprehensive income (loss) is equal to net income (loss).
	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash, accounts payable and accrued expenses and notes payable. The carrying value of cash, accounts payable and accrued expenses approximate their fair value because of their short maturities. The Company believes the carrying amount of its notes payable and convertible debt approximates its fair value based on rates and other terms currently available to the Company for similar debt instruments.
	Cash and Cash Equivalents
	For purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and certificates of deposit and commercial paper with original maturities of 90 days or less to be cash or cash equivalents.
	Concentration of Credit Risk Involving Cash and Cash Equivalents
	The Company’s cash and cash equivalents are held at two financial institutions. At times, the Company’s deposits may exceed Federal Deposit Insurance Corporation (FDIC) coverage limits. The Company has not experienced any losses from maintaining cash accounts in excess of federally insured limits.
	Inventory
	Inventory principally consists of penlights and pigments and is stated at the lower of cost (determined by the first-in, first-out method) or market.
	Property and Equipment
	Property and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, principally five to seven years. Maintenance and repairs of property are charged to operations, and major improvements are capitalized. Upon retirement, sale, or other disposition of property and equipment, the costs and accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in operations.
	Patents and Trademark
	The Company has filed eleven patent applications relating to the company technology. Currently we have 7 U.S. patents, 4 U.S. applications pending for allowance, and 5 foreign applications pending for allowance. The Company has also purchased a trademark. Costs associated with the registration and legal defense of the patents have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents which were determined to be17 to 20 years.
	Long-Lived Assets
	The Company evaluates the recoverability of its long-lived assets in accordance with ASC 360 “Property, Plant, and Equipment.” The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets are measured by a comparison of the carrying amount of an asset to future cash flows expected to be generated by the asset, undiscounted and without interest or independent appraisals. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the assets.
	Deferred Financing Costs
	Costs incurred in securing long-term debt are deferred and amortized, as a charge to interest expense, over the term of the related debt. In the case of long-term debt modifications, the Company follows the guidance provided by ASC 470-50, “Debt – Modification and Extinguishments.”
	Convertible Notes Payable
	Convertible notes payable, for which the embedded conversion feature does not qualify for derivative treatment, are evaluated to determine if the effective or actual rate of conversion per the terms of the convertible note agreement is below market value. In these instances, the Company accounts for the value of the beneficial conversion feature (BCF) as a debt discount, which is then accreted to interest expense over the life of the related debt using the straight-line method which approximates the effective interest method.
	Derivative Instruments
	The Company evaluates its convertible debt, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Topic 480 of the FASB ASC and Topic 815 of the FASB Accounting Standards Codification. The result of this accounting treatment is that the fair value of the embedded derivative, if required to be bifurcated, is marked-to-market at each balance sheet date and recorded as a liability. The change in fair value is recorded in the Statement of Operations as a component of other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.
	In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
	The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.
	Revenue Recognition
	In accordance with Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104, Revenue Recognition (Codified in FASB ASC 605), the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists, (ii) a retailer, distributor or wholesaler receives the goods and acceptance occurs, (iii) the price is fixed or determinable, and (iv) collectability of the revenue is reasonably assured. Subject to these criteria, the Company recognizes revenue from product sales, consisting mainly of pigments and penlights, upon shipment to the customer. Royalty revenue is recognized upon receipt of notification from a customer that the Company’s product has been used in the customer’s production process.
	Income Taxes
	The Company follows FASB ASC 740 when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Tax years from 2011 through 2013 remain subject to examination by major tax jurisdictions.
	Stock-based Payments
	The Company accounts for stock-based compensation under the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method.
	The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.
	All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Any stock options issued to non-employees are recorded as an expense and additional paid-in capital in stockholders’ equity over the applicable service periods.
	Advertising Costs
	Advertising costs are expensed as incurred. Advertising costs were approximately $62,835 and $53,979 for the years ended December 31, 2014 and 2013 and are included in sales and marketing expenses.
	Research and Development Costs
	In accordance with FASB ASC 730, research and development costs are expensed when incurred. Research and development costs for the years ended December 31, 2014 and 2013 were $10,590,271 and $655,840.
	Basic and Diluted Net Income per Share of Common Stock
	The Company follows FASB ASC 260 when reporting Earnings Per Share resulting in the presentation of basic and diluted earnings per share. Since the Company reported a net loss for years ended December 31, 2014 and 2013, common stock equivalents, including convertible preferred stock, convertible debt, stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and dilutive loss per share during the years were the same.
	Segment Information
	The Company is organized and operates as one operating segment wherein the Company’s patented technologies are utilized to address counterfeiting issues. In accordance with ASC 280, Segment Reporting, the chief operating decision-maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Since the Company operates in one segment and provides one group of similar products, all financial segment and product line information required by ASC 280 can be found in the consolidated financial statements.
	Recently Adopted Accounting Pronouncements
	In June 2014, the FASB issued Accounting Standards Update No. 2014-10, Development State Entities (Topic 915), Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this update remove the definition of a development stage entity from the Master Glossary of the Accounting Standard Codification, thereby removing the financial reporting distinction that previously required development stage entities to (1) present inception-to-date information in the statements of income, cash flow, and stockholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principle operations.
	The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which must be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
	For public business entities, the amendment eliminating the exception to the sufficiency-of-equity-at-risk criterion for development stage entities in paragraph 810-10-15-16 should be applied retrospectively for annual reporting periods beginning after December 15, 2015, and interim periods therein.
	Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption entities will no longer present or disclose any information required by Topic 915.
	The Company adopted the amendment retrospectively commencing with the interim period ending June 30, 2014.
	Recently Issued Accounting Pronouncements Not Yet Adopted
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this Update provide guidance about management’s responsibility to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued and to provide related footnote disclosures. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently evaluating the potential impact of this standard.
	Reclassifications
	Certain amounts in the 2013 statement of operations have been reclassified in order for them to conform with the 2014 presentation.

MANAGEMENT_PLANS

MANAGEMENT PLANS	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
MANAGEMENT PLANS	NOTE 2 – MANAGEMENT PLANS
	The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant losses and experienced negative cash flow from operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	The Company does not believe that its existing cash resources will not be sufficient to sustain operations during the next twelve months. The Company currently needs to generate revenue in order to sustain its operations. In the event that the Company cannot generate sufficient revenue to sustain its operations, the Company will need to reduce expenses or obtain financing through the sale of debt and/or equity securities. The issuance of additional equity would result in dilution to existing stockholders. If the Company is unable to obtain additional funds when they are needed or if such funds cannot be obtained on terms acceptable to the Company, the Company may be unable to execute upon the business plan or pay costs and expenses as they are incurred, which could have a material, adverse effect on the business, financial condition and results of operations.
	If sufficient revenues are not generated to sustain operations or additional funding cannot be obtained in the short term, the Company will need to reduce monthly expenditures to a level that will enable the Company to continue until such funds can be obtained.
	Successful completion of the Company’s development program, and the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of sales adequate to support the Company’s cost structure. However, there can be no assurances that the Company will be able to secure additional equity investment or achieve an adequate sales level.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 – PROPERTY AND EQUIPMENT
	Equipment consists of the following:
		December 31,		December 31,
		2014		2013
	Furniture and Fixtures	$	219,871	$	219,871
	Equipment		16,155		16,155
			236,026		236,026
	Less: Accumulated depreciation		161,205		91,952
		$	74,821	$	144,074

PATENTS_AND_TRADEMARK

PATENTS AND TRADEMARK	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
PATENTS AND TRADEMARK	NOTE 4 – PATENTS AND TRADEMARK
	The Company has seven issued patents, four U.S. applications pending, and five foreign applications pending for allowance. Accordingly, costs associated with the registration of these patents and legal defense have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents (17 to 20 years). During the years ended December 31, 2014 and 2013, the Company capitalized $0 and $21,954 of patent costs.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 5 – INCOME TAXES
	The Company follows FASB ASC 740-10-10 whereby an entity recognizes deferred tax assets and liabilities for future tax consequences or events that have been previously recognized in the Company’s financial statements or tax returns. The measurement of deferred tax assets and liabilities is based on provisions of enacted tax law. The effects of future changes in tax laws or rates are not anticipated.
	At December 31, 2014 the Company has a net operating loss (“NOL”) that approximates $26.0 million. Consequently, the Company may have NOL carryforwards available for federal income tax purposes, which would begin to expire in 2019. Due to changes in ownership, a portion of the NOL carryforward may be subject to certain annual limitations imposed under Section 382 of the Internal Revenue Code. Deferred tax assets would arise from the recognition of anticipated utilization of these net operating losses to offset future taxable income.
	The income tax benefit (provision) consists of the following:
		Year Ended			Year Ended
		December 31,			December 31,
		2014			2013
	Current	($	5,505,000	)	$	1,837,000
	Deferred		(372,000	)		3,284,000
	Change in valuation allowance		5,877,000			(5,121,000	)
		$	—		$	—
	The following is a reconciliation of the tax derived by applying the U.S. Federal Statutory Rate of 35% to the earnings before income taxes and comparing that to the recorded tax provisions:
		2014						2013
		Amount			%			Amount			%
	U.S federal income tax benefit at federal statutory rate	$	(2,771,000	)		(35	)	$	(5,718,000	)		(35	)
	State tax, net of federal tax effect		(463,000	)		(6	)		(956,000	)		(6	)
			—			—			—			—
	Deductible share based compensation		—			—			(318,000	)		(2	)
	Non-deductible changes in derviative liability and share based transactions		(2,639,000	)		(33	)		1,895,000			12
	Other		(4,000	)		—			(24,000	)
	Change in valuation allowance		5,877,000			74			5,121,000			31
		$	—			—		$	—			—
	The primary components of the Company’s December 31, 2014 and 2013 deferred tax assets, liabilities and related valuation allowance are as follows:
		December 31,			December 31,
		2014			2013
	Deferred tax asset for NOL carryforwards	$	10,649,000		$	5,144,000
	Deferred tax liability for intangibles		(165,000	)		(165,000	)
	Share based compensation		4,205,000			3,683,000
	Non deductible accrued expenses		—			150,000
	Valuation allowance		(14,689,000	)		(8,812,000	)
		$	—		$	—
	Management has determined that the realization of the net deferred tax asset is not assured and has created a valuation allowance for the entire amount of such benefits.
	The Company follows FASB ASC 740-10, which provides guidance for the recognition and measurement of certain tax positions in an enterprise’s financial statements. Recognition involves a determination whether it is more likely than not that a tax position will be sustained upon examination with the presumption that the tax position will be examined by the appropriate taxing authority having full knowledge of all relevant information.
	The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the consolidated statement of operations. As of December 31, 2014 and 2013, the Company had no unrecognized tax benefits. There were no changes in the Company’s unrecognized tax benefits during the years ended December 31, 2014 and 2013. The Company did not recognize any interest or penalties during 2014 and 2013 related to unrecognized tax benefits.

SENIOR_SECURED_CONVERTIBLE_NOT

SENIOR SECURED CONVERTIBLE NOTES PAYABLE - RELATED PARTIES	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
SENIOR SECURED CONVERTIBLE NOTES PAYABLE - RELATED PARTIES	NOTE 6 – SENIOR SECURED CONVERTIBLE NOTES PAYABLE – RELATED PARTIES
	In February 2006, the Company commenced a private placement of up to $800,000 principal amount of 10% senior secured convertible promissory notes due twelve months from the date of issue to certain Company shareholders and other accredited investors. As of December 31, 2006, the Company completed this private placement by selling all notes payable totaling $800,000. The notes are secured by a first priority lien on all of the tangible and intangible personal property of the Company. In May 2007, the due date of these notes was extended to August 2008 and the interest rate increased to 12% per annum during the extension period. In June 2011, the interest rate on all of the notes was reset to 10% and $596,500 of the notes and accrued interest was extended until September 15, 2015. During the fourth quarter of 2012 the remaining $178,749 of unextended notes and the associated accrued interest were extended to September 30, 2015. In June 2013, $225,000 of these notes payable plus accrued interest of $181,125 were converted into 7.4 million shares of the Company’s common stock, which was valued at $1,628,000. The excess of the fair value of the Company’s common stock over the value of the notes payable and accrued interest was recorded as loss on extinguishment of debt in accordance with FASB ASC 470-50.
	During the fourth quarter of 2013, $220,000 of senior convertible notes plus accrued interest of $395,000, were converted into 7,900,000 shares of common stock. Since this transaction was with related parties, the conversion was treated as a capital transaction in accordance with FASB ASC 470-50-40-3.
	As of December 31, 2014 and December 31, 2013, the outstanding principal balance on these notes was $114,000 and $330,249. Accrued interest at December 30, 2014 and December 31, 2013 amounted to $112,885 and $300,677.
	During the second quarter of 2014, $216,249 of principal of the Company’s outstanding senior convertible notes held by a significant shareholder of the Company, plus accrued interest of $208,339, were converted into 8,448,519 shares of common stock. The excess of the fair value of the Company’s common stock over the value of the notes payable and accrued interest, $82,000, was recorded as loss on extinguishment of debt in accordance with FASB ASC 470-50.
	As of December 31, 2014, the outstanding principal balance on these notes was $114,000. Accrued interest at December 31, 2014 amounted to $112,885.
	If an equity financing with total proceeds of more than $5,000,000 occurs while any of these notes are outstanding, holders of notes will have the right, at their option, to convert the outstanding principal and interest of the notes into shares of common stock at a discount of 30% of the price per share in the qualified financing. Since the embedded conversion feature is contingent upon the occurrence of the qualified financing, the value of the contingent conversion feature, if beneficial, will be recognized if the triggering event occurs and the contingency is resolved.

CONVERTIBLE_NOTES_PAYABLE

CONVERTIBLE NOTES PAYABLE	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 7 – CONVERTIBLE NOTES PAYABLE
	During 2007, the Company commenced a private placement of up to $400,000 principal amount of 10% Convertible Promissory Notes originally due in August 2008 (the “Notes”). The Company raised $375,000 under this private placement in 2007 and the remaining $25,000 was raised in 2008. Previously $260,000 of the Notes were converted into shares of the Company’s common stock. Holders of Notes will have the right, at their option, to convert the outstanding principal and interest of the Notes into shares of the Company’s Series A Preferred Stock at any time and from time to time at the option of the holder at the initial conversion price of $0.005333 per share. It is the intention, however, that the option holder will convert the Notes into shares of the Company’s common stock. The Notes are unsecured.
	In accordance with ASC 470, a beneficial conversion feature of $375,000 and $25,000 was required to be recorded in 2007 and 2008, respectively, since the fair value of the Company’s common stock at the date of issuance ($0.016 per share) was greater than the conversion price of $0.005333 per share. The value of the beneficial conversion feature was recorded to additional paid-in capital with the offset to discount on notes payable. The debt discount was accreted to interest expense over the one-year original term of the notes.
	In August 2009, noteholders exercised their option to convert $260,000 of the notes payable plus accrued interest into 48,750,000 shares of common stock. The noteholder of the remaining $140,000 under this convertible note issue agreed to extend the maturity date of these notes to September 30, 2015 at an interest rate of 10% per annum. Additionally, the noteholder agreed in writing to suspend its right to convert its note until such as the Company’s authorized shares have been increased. Remaining shares to be potentially issued under this convertible note issue is 26,250,000.
	On March 19, 2013, the investor holding $140,000 of convertible notes transferred $14,000 of the $140,000 convertible notes to the Vice Chairman of the Company. Also on March 19, 2013, the investor agreed to convert $28,000 of the investor’s remaining $126,000 of convertible notes into 5,250,000 shares of the Company’s common stock.
	On March 19, 2013, the Vice Chairman of the Company agreed to convert $14,000 of convertible notes into 2,625,000 of the Company’s common stock.
	During the fourth quarter of 2013, the remaining $98,000 of convertible notes plus accrued interest of $87,150 were converted into 12,375,000 shares of common stock. Since this conversion was with a related party it was treated as a capital transaction in accordance with FASB ASC 470-50-40-3.

WARRANT_LIABILITY

WARRANT LIABILITY	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
WARRANT LIABILITY	NOTE 9 – WARRANT LIABILITY
	On December 31, 2012, the Company entered into an Investment Agreement, a Technology and Service Agreement, a Patent and Technology License Agreement and an Asset Purchase Agreement with VerifyMe, and on the same date entered into a Technology and Service Agreement with Zaah Technologies, Inc. (collectively with the VerifyMe agreements, the “Agreements”). Contemplated by those Agreements were warrants issuances by the Company for the purchase of the Company’s common stock.
	The warrants associated with these Agreements are subject to anti-dilution adjustments outlined in the Agreements. In accordance with FASB ASC 815, the warrants were classified as a liability in the total amount of $2.4 million at December 31, 2012. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of December 31, 2014 and December 31, 2013, the fair value of the warrant liability was $787,544 and $3,700,000.
	On January 1, 2014, the Company issued warrants to purchase 6,349,206 shares of the Company’s common stock as consideration for technology received from VerifyMe under to the Patent and Technology License Agreement dated December 31, 2012. The warrants are exercisable at $0.10 per share. The warrants are subject to anti-dilution adjustments outlined in the Agreement. In accordance with FASB ASC 815, the warrants were classified as a liability with an initial fair value of $444,000, which was immediately expensed as research and development costs. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of December 31, 2014, the fair value of the warrant liability was $121,209.
	The Company made the payment of warrants to VerifyMe on a good faith basis, based on the assumption that the technology conveyed to the Company would be patentable and licensable. The Company has not reached a conclusion that the technology will be patentable and licensable, and can provide no assurance to this effect.
	Should the Company ultimately conclude that the technology received from VerifyMe is patentable and licensable, the Company would be required to make, on January 1, 2015, an additional payment pursuant to Patent and Technology Agreement in the amount of $4,500,000, to be paid by issuing (i) a number of shares of common stock equal to (x) $4,500,000 divided by (y) a price which equals a 10% discount to the market price at the time of issuance and (ii) warrants to purchase an equal number of shares of common stock exercisable at a price of $0.10 per share. Based upon the current share price of $0.04 per share, this would result in the issuance of approximately an additional 125 million shares of common stock and warrants to purchase an additional 125 million shares. The $4,500,000 was accrued at December 31, 2014. The number of warrants to be issued based on a stock price of $0.02 at December 31, 2014 was 250 million warrants. The warrants were valued at $4,892,089 using the Black-Scholes pricing model to calculate the grant-date fair value of the warrants with the following assumptions: no dividend yield, expected volatility of 229.1%, risk free interest rate of 1.65% and expected life of five years.

CONVERTIBLE_PREFERRED_STOCK

CONVERTIBLE PREFERRED STOCK	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
CONVERTIBLE PREFERRED STOCK	NOTE 10 – CONVERTIBLE PREFERRED STOCK
	Subscription Agreement
	The Company entered into a Subscription Agreement with VerifyMe on January 31, 2013 (the “Subscription Agreement”). Under the terms of the Subscription Agreement, VerifyMe subscribed to purchase 33,333,333 shares of the Company’s Series A preferred stock (the “Preferred Stock”) and a warrant to purchase 33,333,333 shares of the Company’s common stock at an exercise price of $0.12 per share, for $1 million.
	At any time before January 31, 2015, VerifyMe has the right, but not the obligation, to require the Company to repurchase all, but not less than all, of the capital stock of the Company and warrants exercisable for capital stock of the Company held by VerifyMe in exchange for the price originally paid by VerifyMe therefor upon the occurrence of any of the following events:(i) the consummation of any bona fide business acquisition, (ii) the incurrence of any indebtedness by the Company in an amount in excess of $2 million, (iii) the issuance or sale of any security having a preference on liquidation senior to common stock, or (iv) the sale by the Company of capital stock or warrants exercisable for its capital stock at a price below $0.03 per share. This right has not been exercised.
	In accordance with FASB ASC 480 and 815, the Preferred Stock has been classified as permanent equity and was valued at $1 million at January 31, 2013.
	The conversion feature of the Preferred Stock is an embedded derivative, which is classified as a liability in accordance with FASB ASC 815 and was valued in accordance with FASB ASC 470 as a beneficial conversion feature at a fair value of $1 million at January 31, 2013, $0 at December 31, 2014 and $800,000 at December 31, 2013. This was classified as an embedded derivative liability and a discount to Preferred Stock. Because the Preferred Stock can be converted at any time, the full amount of the original fair value was accreted and classified as a reduction to the discount on Preferred Stock and a deemed dividend distribution in the full amount of $1 million, in 2013.
	The warrants associated with the Preferred Stock were also classified as a liability since they are subject to anti-dilutive adjustments outlined in the warrant agreement and valued at a fair market value of $2,995,791 at January 31, 2013. Because this amount was entirely in excess of the transaction price, this amount was recorded as a charge to expenses of $2,995,791 in 2013. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of December 31, 2014 and December 31, 2013, the fair value of the warrants was $494,939 and $2,300,000, respectively.
	The Preferred Stock has a preference in liquidation that the holders of the Preferred Stock are to be paid out of assets available for distribution prior to holders of common stock. The Preferred Stockholders may cast the number of votes equal to the number of whole shares of common stock into which the shares of Preferred Stock can be converted. In addition, the Preferred Stockholders are to be paid dividends, based on the number of shares of Preferred Stock as if the shares had been converted to common shares, prior to the common stockholders receiving a dividend.
	The conversion price of the shares of Preferred Stock is currently $0.03 per share.
	In August 2013, VerifyMe elected to convert in a cashless transaction an equal number of shares of Preferred Stock valued at $366,667 to 12,222,222 shares of common stock.

FAIR_VALUE_OF_FINANCIAL_INSTRU

FAIR VALUE OF FINANCIAL INSTRUMENTS	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	NOTE 11 – FAIR VALUE OF FINANCIAL INSTRUMENTS
	Derivative Liabilities
	For purposes of determining whether certain instruments are derivatives for accounting treatment, the Company follows the accounting standard that provides guidance for determining whether an equity-linked financial instrument, or embedded feature, is indexed to an entity’s own stock. The standard applies to any freestanding financial instruments or embedded features that have the characteristics of a derivative, and to any freestanding financial instruments that are potentially settled in an entity’s own common stock.
	Liabilities measured at fair value on a recurring basis are summarized as follows:
		Level 1			Level 2		Level 3		Total
	Derivative liability related to fair value of beneficial conversion feature	$	—		$	—	$	—	$	—
	Derivative liability related to fair value of warrants		—			—		6,370,709		6,370,709
	Total	$	—		$	—	$	6,370,709	$	6,370,709
	The following table details the approximate fair value measurements within the fair value hierarchy of the Company’s derivative liabilities using Level 3 inputs:
		Total
	Balance at January 1, 2014	$	6,000,000
	Additional Warrants issued January 2014		444,000
	Additional Warrants issued June 2014		34,222
	Additional Warrants issued 3rd Quarter 2014		166,791
	Additional Warrants Issued 4th Quarter 2014		4,903,900
	Change in fair value of derivative liabilities		(5,178,204	)
	Balance at December 31, 2014	$	6,370,709
	As of December 31, 2014, the beneficial conversion feature of the Preferred Stock is treated as an embedded derivative liability and changes in the fair value were recognized in earnings. The Preferred Stock shares are convertible into shares of the Company’s common stock, which did traded in an active securities market, therefore the embedded derivative liability was valued using the following market based inputs:
	Closing trade price of Common Stock	$	0.02
	Series A Preferred Stock Conversion price	$	0.03
	Intrinsic value of conversion option per share	$	—
	The Company has no assets that are measured at fair value on a recurring basis. There were no assets or liabilities measured at fair value on a non-recurring basis during the year ended December 31, 2014.
	As of December 31, 2014, the Company’s outstanding warrants were treated as derivative liabilities and changes in the fair value were recognized in earnings. These common stock purchase warrants did not trade in an active securities market, and as such, the Company estimated the fair value of these warrants using Black-Scholes and the following assumptions:
		December 31, 2014
	Annual Dividend Yield		0.00%
	Expected Life (Years)		3.0 - 4.69
	Risk-Free Interest Rate		1.10% -1.65%
	Expected Volatility		174.8% - 203.6%
	Expected volatility was based primarily on historical volatility. Historical volatility was computed using daily pricing observations for recent periods. The Company believes this method produced an estimate that was representative of the Company’s expectations of future volatility over the expected term of these warrants. The Company had no reason to believe future volatility over the expected remaining life of these warrants was likely to differ materially from historical volatility. The expected life was based on the remaining contractual term of the warrants. The risk-free rate was based on the U.S. Treasury rate that corresponded to the expected term of the warrants.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 12 – STOCKHOLDERS’ EQUITY
	In January and February 2013, the Company received $185,000 from the sale of 3,700,000 units from private placements consisting of shares of the Company’s common stock and warrants to purchase shares of the Company’s common stock at an exercise price of $0.10 per share. The shares and warrants were sold in units with each unit comprised of one share and one warrant at a purchase price of $.05 per unit.
	In January 2013, the Company commenced private placements consisting of shares of the Company’s common stock and warrants to purchase shares of the Company’s common stock at an exercise price of $0.12 per share. The shares and warrants were sold in units with each unit comprised of one share and one warrant at a purchase price of $.045 per unit. The company sold 1,111,111 units and raised $50,000.
	On February 1, 2013, an investor exercised a warrant to purchase 1 million shares of the Company’s common stock that raised $10,000 for the Company.
	In February and March 2013, four investors exercised options to purchase 3,335,000 shares of the Company’s common stock that raised $17,919 for the Company.
	On January 1, 2014, under the terms of the Patent and Technology License Agreement, the Company issued 6,349,206 shares of common stock to VerifyMe, in addition to the warrants described in Note 8 above. The shares were issued in payment for the technology received. Under the agreement, $400,000 worth of the Company’s common stock was to be paid by the Company to VerifyMe at a 10% discount to the market at time of payment. The closing price was $0.07 per share discounted 10% to $0.063. The $400,000 payment divided by the $0.063 per share resulted in 6,349,206 shares to be issued. The entire $400,000 payment was expensed to research and development.
	During the second quarter of 2014, $216,249 of principal of the Company’s outstanding senior convertible notes plus accrued interest of $208,339, were converted into 8,448,519 shares of common stock. The excess of the fair value of the Company’s common stock over the value of the notes payable and accrued interest, $82,000, was recorded as loss on extinguishment of debt in accordance with FASB ASC 470-50.

STOCK_OPTIONS

STOCK OPTIONS	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK OPTIONS	NOTE 13 – STOCK OPTIONS
	During 1999, the Board of Directors (“Board”) of the Company adopted, with the approval of the stockholders, a Stock Option Plan. In 2000, the Board superseded that plan and created a new Stock Option Plan, pursuant to which it is authorized to grant options to purchase up to 1.5 million shares of common stock. On December 17, 2003, the Board, with approval of the stockholders, superseded the 2000 plan and created the 2003 Stock Option Plan (the “2003 Plan”). Under the 2003 Plan the Company is authorized to grant options to purchase up to 18,000,000 shares of common stock to the Company’s employees, officers, directors, consultants, and other agents and advisors. The Plan is intended to permit stock options granted to employees under the Plan to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended (“Incentive Stock Options”). All options granted under the 2003 Plan, which are not intended to qualify as Incentive Stock Options, are deemed to be non-qualified options (“Non-Statutory Stock Options”).
	During 2013, our Board adopted a new omnibus incentive compensation plan that was ratified by the shareholders at the 2013 annual meeting, (the “2013 Plan”) which will serve as the successor incentive compensation plan to the 2003 Plan, and will provide the Company with an comprehensive plan to design and structure grants of stock options, stock units, stock awards, stock appreciation rights and other stock-based awards for our employees, non-employee directors and certain consultants and advisors. Our Board of Directors believes that the availability of (i) 20,000,000 new shares of our common stock, plus (ii) the 1,274,004 shares of our common stock available for issuance under the 2003 Plan, will be sufficient to meet the objective.
	As of December 31, 2014, there are 23,225,996 options that have been issued, and 14,774,004 options that are available to be issued under the Plan.
	The 2013 Plan is administered by a committee of the Board (“Compensation Committee”) which determines the persons to whom awards will be granted, the number of awards to be granted and the specific terms of each grant, including the vesting thereof, subject to the provisions of the plan.
	In connection with Incentive Stock Options, the exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company). The aggregate fair market value (determined at the time of the grant) of stock for which an employee may exercise Incentive Stock Options under all plans of the company shall not exceed $1,000,000 per calendar year. If any employee shall have the right to exercise any options in excess of $100,000 during any calendar year, the options in excess of $100,000 shall be deemed to be Non-Statutory Stock Options, including prices, duration, transferability and limitations on exercise.
	The Company issued Non-Statutory Stock Options pursuant to contractual agreements with non-employees. Options granted under the agreements are expensed when the related service or product is provided.
	Determining the appropriate fair value of stock-based awards requires the input of subjective assumptions. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value represent management’s best estimates and involve inherent uncertainties and judgments.
	On January 22, 2013, the Company issued options to an employee to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.05 per share, with a term of ten years. The options vest as follows: 250,000 immediately, 250,000 on the first anniversary of the grant date and 500,000 on the second anniversary of the grant date. The Company used the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 222%, risk-free interest rate of 1.9% and expected option life of ten years. The fair value of the options issued was $99,972, of which $25,000 was expensed immediately and the remainder is being expensed over the vesting terms. The total expense for the years ended December 31, 2014 and 2013 was $26,500 and $12,600.
	On February 25, 2013, the Company issued options to an employee to purchase 500,000 shares of the Company’s common stock at an exercise price of $0.05 per share, with a term of ten years. The options vest as follows: 200,000 on the first anniversary of the grant date, 200,000 on the second anniversary of the grant date and 100,000 on the third anniversary of the grant date. The Company used the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 259%, risk-free interest rate of 1.9% and expected option life of ten years. The fair value of options issued was $89,998. The total expense recognized for the three months ended March 31, 2013 was $5,000. The employee was dismissed and the options were cancelled during the three months ended June 30, 2013. The total expense recognized of $5,000 was reversed upon cancellation of the options.
	On March 13, 2013, the Company issued an option to purchase 2,000,000 shares of the Company’s common stock at an exercise price of $0.05 per share, with a term of ten years, to a member of the Board. The options vested 50% immediately and 50% on March 13, 2014. The Company used the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 235%, risk-free interest rate of 2.0% and expected option life of ten years. The fair value of the option issued was $439,963 of which $219,982 was expensed immediately and the remainder will be expensed over one year. The total expense recognized for the years ended December 31, 2014 and 2013 was $43,394 and $55,447.
	On May 4, 2013, the Company issued an option to purchase 2,000,000 shares of the Company’s common stock at an exercise price of $0.05 per share, with a term of ten years, to a member of the Board. The options vest 50% immediately and 50% on May 4, 2014. The Company used the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 235%, risk-free interest rate of 1.78% and expected option life of ten years. The fair value of the option issued was $460,000 of which $230,000 was expensed immediately and the remainder will be expensed over one year. The total expense for the three and years ended December 31, 2014 and 2013 was $78,137 and $57,973.
	Effective October 8, 2012, the Company entered into a three year agreement with the then Vice Chairman of the Board of the Company, with an annual compensation of $200,000 per year. In addition, upon execution of the agreement the Company agreed to issue 10 year options to the then Vice Chairman to purchase 5% of the shares of the Company’s fully diluted common stock at an exercise price of $.05 per share, subsequent to the Company receiving funding of $2.5 million. The Company raised the $2.5 million in funding and on June 25, 2013, the Company issued the Vice Chairman 19 million 10 year options in satisfaction of the 5% of the shares of the Company’s fully diluted common stock clause. The Company used the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 146.1%, risk-free interest rate of 2.6% and expected option life of ten years. The fair value of options issued was $3,767,700, which was expensed immediately.
	Effective October 16, 2012, the Company entered into a three year agreement with the then President and current Chief Executive Officer of the Company with an annual compensation of $200,000 per year. In addition, upon execution of the agreement the Company agreed to issue 10 year options to the President to purchase 5% of the shares of the Company’s fully diluted common stock at an exercise price of $.05 per share, subsequent to the Company receiving funding of $2.5 million and on June 25, 2013, the Company issued the President and Chief Executive Officer 19 million 10 year options in satisfaction of the 5% of the shares of the Company’s fully diluted common stock clause. The Company used the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 146.1%, risk-free interest rate of 2.6% and expected option life of ten years. The fair value of options issued was $3,767,700, which was expensed immediately.
	On September 30, 2013, the Company issued an option to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.15 per share, with a term of ten years, to the Company’s Chief Operating Officer. The options vest 50% after the first year and 50% at the end of 24 months after the grant date. The Company used the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of ranging from 268.4% to 272.8%, risk-free interest rate of 1.39% and expected option life ranging from 10 years. The fair value of the option issued was $99,840. The total expense for the years ended December 31, 2014 and 2013 was $62,395 and $18,903, respectively.
	On December 2, 2013, the Company issued an option to purchase 1 million shares of the Company’s common stock at an exercise price of $0.15 per share, with a term of ten years, to the Company’s Chief Financial Officer. The options vest 50% after the first year and 50% at the end of 24 months. The Company used the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of ranging from 266.1%, risk-free interest rate of 2.64% and expected option life of 10 years. The fair value of the option issued was $79,994, which will be expensed over the vesting term. The total expense for the years ended December 31, 2014 and 2013 was $49,916 and $15,123, respectively.
	On March 28, 2014, the Company issued options to purchase an aggregate of 6,000,000 shares of the Company’s common stock at an exercise price of $0.05 per share, with a term of ten years, to a member of the Board of Directors. The fair value of options issued was $599,893 of which all was expensed immediately. These options were valued using the Black-Scholes option pricing model to calculate the grant-date fair value of the options, with the following assumptions: no dividend yield, expected volatility of 229%, risk-free interest rate of 2.73% and expected option life of ten years.
	On March 28, 2014 at the urging of the Company’s previous Chairman, Michael Sonnenreich, and after discussion by the Board and suggestions by Board Observers attending the meeting, the Board unanimously voted to extend the exercise period of all existing 10 year options, for a full ten years (as opposed to six months) regardless of their status with the Company. This charge was memorialized and sent in writing to previous Directors by then general counsel Morgan, Lewis & Bockius.
	The following tables summarize non-employee stock option/warrant activity of the Company since December 31, 2012:
							Weighted Average
		Option/Warrant			Exercise		Exercise
		Shares			Price		Price
	Outstanding, December 31, 2012		82,807,221		$	0.00125 to $0.20	$	0.01
	Granted		38,144,444			0.10 - 0.15		0.03
	Exercised		(9,435,000	)		0.00125 - 0.07		—
	Expired		—			—		—
	Outstanding, December 31, 2013		111,516,665			0.00125 to 0.20		0.09
	Granted		10,349,209			0.05 - 0.10		0.01
	Exercised		—			—		—
	Expired		(700,000	)		—		—
	*Outstanding, December 31, 2014		121,165,874		$	0.01 to $.20	$	0.1
	*Exercisable, December 31, 2014		121,165,874		$	0.01 to $.20	$	0.1
	Weighted Average Remaining Life, Exercisable, December 31, 2014 (years)		5.7
	* Does not include 250,000,000 warrants that are due to be issued on January 1, 2015. The warrants has a fair value of $4,892,089 and are reflected in warrant liabilities on the balance sheet as of December 31, 2014 and the corresponding expense is reflected in research and development expense.
	A summary of incentive stock option transactions for employees since December 31, 2013 is as follows:
		Option/Warrant			Exercise Price		Weighted Average
		Shares					Exercise Price
	Outstanding, December 31, 2012		15,766,667		$	0.00125 to $0.10	$	0.06
	Granted		45,500,000			0.05 - 0.15		0.04
	Exercised		(900,000	)		0.00125		—
	Expired		(500,000	)		0.05		—
	Outstanding, December 31, 2013		59,866,667			0.00125 to 0.15		0.06
	Granted		6,000,000			0.05		0.01
	Exercised		(12,000,000	)		0.05		0.01
	Expired		—			—		—
	Outstanding, December 31, 2014		53,866,667		$	0.05 - $0.15	$	0.05
	Exercisable, December 31, 2014		51,366,667		$	0.05 - $0.15	$	0.06
	Weighted Average Remaining Life, Exercisable, December 31, 2014 (years)		8.3

OPERATING_LEASES

OPERATING LEASES	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
OPERATING LEASES	NOTE 14 – OPERATING LEASES
	For the year ended December 31, 2014 and 2013, total rent expense under leases amounted to $65,950 and $59,272. At December 31, 2014, the Company was obligated under various non-cancelable operating lease arrangements for property as follows:
	2015		74,637
	2016		31,605
		$	106,242

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 15 – RELATED PARTY TRANSACTIONS
	During the fourth quarter of 2013, the company converted outstanding debt owed to shareholders into 25,974,697 shares of common stock (See Notes 6,7,8).
	At December 31, 2014 and 20123, two and five shareholders of the Company held $114,000 and $330,249 of the senior secured convertible notes payable and were owed accrued interest of $112,505 and 300,677.
	One shareholder held $140,000 of convertible notes payable as of December 31, 2012, that was satisfied by December 31, 2013.
	At December 31, 2014, two stockholders of the Company held $114,000 in principal of the Company’s senior secured convertible notes payable, and were owed accrued interest of $112,505 related to such notes.

CONTINGENCIES

CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES	NOTE 16 – CONTINGENCIES
	In October 2010, the Company filed suit in the Western District of Pennsylvania against WS Packaging Group, Inc. (“WS”) alleging that WS infringed on one of the Company’s patents in the manufacture of MONOPOLY game pieces on behalf of McDonald’s Corp. On June 4, 2012, both WS and the Company filed a stipulation to dismiss the action without prejudice and enter into settlement negotiations. There are no ongoing negotiations.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 17 – SUBSEQUENT EVENTS
	On February 10, 2015, the Company issued a note payable for $25,000, bearing interest at 5.0% to an accredited investor and director of the Company. The note is due on June 10, 2015.
	On February 15, 2015, a Board member advised the Company that her two year term as a Director expired on February 21, 2015 and that she would not stand for re-election or continue to serve as a director.
	On February 26, 2015, a Board member advised the Company that he was resigning from the Board of Directors.
	At December 31, 2014, three stockholders of the Company held $323,000 in principal of the Company’s notes payable, and were owed accrued interest of $31,845 related to such notes.
	On March 27, 2015, the Company issued a note payable for $111,102, bearing interest at 8.0% to an accredited investor. The note is due on June 25, 2015. On March 20, 2014, VerifyMe waived its contractual rights as it relates to this transaction.
	On March 30, 2015, the Company was advised by the United States Patent and Trademark Office (“USPTO”) that its petition for an unintentional delayed payment for an unpaid maintenance fee to reinstate its patent was granted by the USPTO. The patent, for a counterfeiting ink detection system, was granted on November 2, 2004.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Nature of the Business	Nature of the Business
	LaserLock Technologies, Inc. (the “Company”) was incorporated in the State of Nevada on November 10, 1999. The Company is based in Washington, D.C. and its common stock is traded on the OTCQB under the ticker symbol “LLTI”. A high-tech solutions company in the field of authenticating people and products, LaserLock offers state-of-the-art solutions to combat identity fraud and counterfeiting utilizing multi-factor authentication and a suite of security pigments for governments, health care providers, the gaming industry, the financial services industry and high-end retailers.
	The Company invests in developing new proprietary color shifting inks that it believes will allow it to penetrate broader markets and result in increased revenues. The Company refines its technologies and their applications, and now has what it believes to be one of the most cost effective and efficient authentication technologies available. Its most recent technology takes advantage of the new ubiquitous energy efficient fluorescent lighting to change the color of ink, resulting in numerous potential new applications ranging from credit cards to drivers licenses, passports, stock certificates, clothing labels, currency, ID cards, and tax stamps. The technologies can also be used to protect DVDs, apparel, pharmaceuticals, and virtually any other physical product.
	The Company’s digital solution is a multi-platform (iOS and Android) strong authentication solution that integrates biometrics and geo-location tagging. The solution completely eliminates passwords and the inherently weak security they provide. The solution also removes the user complexity associated with having to manage many complex passwords. The solution can be delivered either as a high availability cloud service, managed by the Company, or as licensed software product for operation on the client’s premises.
	The solution integrates three independent authentication factors – something you have (for instance a smartphone), something you know (for instance a color gesture swipe) and something you are (for instance your facial geometry)—into a simple, fast, intuitive solution. The system can also accurately determine the precise location of the individual using a variety of mechanisms including GPS, cell tower triangulation, IP or WIFI address. Because the solution incorporates biometrics it completely eliminates the possibility that users might share their authentication credentials. The combination of biometrics and geolocation provides extremely strong transactional evidence, making it nearly impossible for an end-user to refute having been part of a transaction.
	The Company’s activities are subject to significant risks and uncertainties, including the need to secure additional funding to operationalize the Company’s current technology.
Basis of Presentation	Basis of Presentation
	The accompanying financial statements are presented in accordance with accounting principles generally accepted in the United States of America.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Comprehensive Income	Comprehensive Income
	The Company follows Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”) 220 in reporting comprehensive income. Comprehensive income is a more inclusive financial reporting methodology that includes disclosure of certain financial information that historically has not been recognized in the calculation of net income. Since the Company has no items of other comprehensive income (loss), comprehensive income (loss) is equal to net income (loss).
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash, accounts payable and accrued expenses and notes payable. The carrying value of cash, accounts payable and accrued expenses approximate their fair value because of their short maturities. The Company believes the carrying amount of its notes payable and convertible debt approximates its fair value based on rates and other terms currently available to the Company for similar debt instruments.
Cash and Cash Equivalents	Cash and Cash Equivalents
	For purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and certificates of deposit and commercial paper with original maturities of 90 days or less to be cash or cash equivalents.
Concentration of Credit Risk Involving Cash and Cash Equivalents	Concentration of Credit Risk Involving Cash and Cash Equivalents
	The Company’s cash and cash equivalents are held at two financial institutions. At times, the Company’s deposits may exceed Federal Deposit Insurance Corporation (FDIC) coverage limits. The Company has not experienced any losses from maintaining cash accounts in excess of federally insured limits.
Inventory	Inventory
	Inventory principally consists of penlights and pigments and is stated at the lower of cost (determined by the first-in, first-out method) or market.
Property and Equipment	Property and Equipment
	Property and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, principally five to seven years. Maintenance and repairs of property are charged to operations, and major improvements are capitalized. Upon retirement, sale, or other disposition of property and equipment, the costs and accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in operation
Patents and Trademark	Patents and Trademark
	The Company has filed eleven patent applications relating to the company technology. Currently we have 7 U.S. patents, 4 U.S. applications pending for allowance, and 5 foreign applications pending for allowance. The Company has also purchased a trademark. Costs associated with the registration and legal defense of the patents have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents which were determined to be17 to 20 years.
Long-Lived Assets	Long-Lived Assets
	The Company evaluates the recoverability of its long-lived assets in accordance with ASC 360 “Property, Plant, and Equipment.” The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets are measured by a comparison of the carrying amount of an asset to future cash flows expected to be generated by the asset, undiscounted and without interest or independent appraisals. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the assets.
Deferred Financing Costs	Deferred Financing Costs
	Costs incurred in securing long-term debt are deferred and amortized, as a charge to interest expense, over the term of the related debt. In the case of long-term debt modifications, the Company follows the guidance provided by ASC 470-50, “Debt – Modification and Extinguishments.”
Convertible Notes Payable	Convertible Notes Payable
	Convertible notes payable, for which the embedded conversion feature does not qualify for derivative treatment, are evaluated to determine if the effective or actual rate of conversion per the terms of the convertible note agreement is below market value. In these instances, the Company accounts for the value of the beneficial conversion feature (BCF) as a debt discount, which is then accreted to interest expense over the life of the related debt using the straight-line method which approximates the effective interest method.
Derivative Instruments	Derivative Instruments
	The Company evaluates its convertible debt, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Topic 480 of the FASB ASC and Topic 815 of the FASB Accounting Standards Codification. The result of this accounting treatment is that the fair value of the embedded derivative, if required to be bifurcated, is marked-to-market at each balance sheet date and recorded as a liability. The change in fair value is recorded in the Statement of Operations as a component of other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.
	In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
	The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date.
Revenue Recognition	Revenue Recognition
	In accordance with Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104, Revenue Recognition (Codified in FASB ASC 605), the Company recognizes revenue when (i) persuasive evidence of a customer or distributor arrangement exists, (ii) a retailer, distributor or wholesaler receives the goods and acceptance occurs, (iii) the price is fixed or determinable, and (iv) collectability of the revenue is reasonably assured. Subject to these criteria, the Company recognizes revenue from product sales, consisting mainly of pigments and penlights, upon shipment to the customer. Royalty revenue is recognized upon receipt of notification from a customer that the Company’s product has been used in the customer’s production process.
Income Taxes	Income Taxes
	The Company follows FASB ASC 740 when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Tax years from 2011 through 2013 remain subject to examination by major tax jurisdictions.
Stock-based Payments	Stock-based Payments
	The Company accounts for stock-based compensation under the provisions of ASC 718, Compensation—Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method.
	The Company accounts for stock-based compensation awards to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees (“ASC 505-50”). Under ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable.
	All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Any stock options issued to non-employees are recorded as an expense and additional paid-in capital in stockholders’ equity over the applicable service periods.
Advertising Costs	Advertising Costs
	Advertising costs are expensed as incurred. Advertising costs were approximately $62,835 and $53,979 for the years ended December 31, 2014 and 2013 and are included in sales and marketing expenses.
Research and Development Costs	Research and Development Costs
	In accordance with FASB ASC 730, research and development costs are expensed when incurred. Research and development costs for the years ended December 31, 2014 and 2013 were $10,590,271 and $655,840.
Basic and Diluted Net Income per Share of Common Stock	Basic and Diluted Net Income per Share of Common Stock
	The Company follows FASB ASC 260 when reporting Earnings Per Share resulting in the presentation of basic and diluted earnings per share. Since the Company reported a net loss for years ended December 31, 2014 and 2013, common stock equivalents, including convertible preferred stock, convertible debt, stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and dilutive loss per share during the years were the same.
Segment Information	Segment Information
	The Company is organized and operates as one operating segment wherein the Company’s patented technologies are utilized to address counterfeiting issues. In accordance with ASC 280, Segment Reporting, the chief operating decision-maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Since the Company operates in one segment and provides one group of similar products, all financial segment and product line information required by ASC 280 can be found in the consolidated financial statements.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements
	In June 2014, the FASB issued Accounting Standards Update No. 2014-10, Development State Entities (Topic 915), Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this update remove the definition of a development stage entity from the Master Glossary of the Accounting Standard Codification, thereby removing the financial reporting distinction that previously required development stage entities to (1) present inception-to-date information in the statements of income, cash flow, and stockholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principle operations.
	The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which must be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.
	For public business entities, the amendment eliminating the exception to the sufficiency-of-equity-at-risk criterion for development stage entities in paragraph 810-10-15-16 should be applied retrospectively for annual reporting periods beginning after December 15, 2015, and interim periods therein.
	Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption entities will no longer present or disclose any information required by Topic 915.
	The Company adopted the amendment retrospectively commencing with the interim period ending June 30, 2014.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this Update provide guidance about management’s responsibility to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued and to provide related footnote disclosures. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company is currently evaluating the potential impact of this standard.
Reclassifications	Reclassifications
	Certain amounts in the 2013 statement of operations have been reclassified in order for them to conform with the 2014 presentation.

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Equipment	Equipment consists of the following:
		December 31,		December 31,
		2014		2013
	Furniture and Fixtures	$	219,871	$	219,871
	Equipment		16,155		16,155
			236,026		236,026
	Less: Accumulated depreciation		161,205		91,952
		$	74,821	$	144,074

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Benefit (Provision)	The income tax benefit (provision) consists of the following:
		Year Ended			Year Ended
		December 31,			December 31,
		2014			2013
	Current	($	5,505,000	)	$	1,837,000
	Deferred		(372,000	)		3,284,000
	Change in valuation allowance		5,877,000			(5,121,000	)
		$	—		$	—
Income Tax Reconciliation	The following is a reconciliation of the tax derived by applying the U.S. Federal Statutory Rate of 35% to the earnings before income taxes and comparing that to the recorded tax provisions:
		2014						2013
		Amount			%			Amount			%
	U.S federal income tax benefit at federal statutory rate	$	(2,771,000	)		(35	)	$	(5,718,000	)		(35	)
	State tax, net of federal tax effect		(463,000	)		(6	)		(956,000	)		(6	)
			—			—			—			—
	Deductible share based compensation		—			—			(318,000	)		(2	)
	Non-deductible changes in derviative liability and share based transactions		(2,639,000	)		(33	)		1,895,000			12
	Other		(4,000	)		—			(24,000	)
	Change in valuation allowance		5,877,000			74			5,121,000			31
		$	—			—		$	—			—
Deferred Tax Assets, Liabilities And Related Valuation Allowance	The primary components of the Company’s December 31, 2014 and 2013 deferred tax assets, liabilities and related valuation allowance are as follows:
		December 31,			December 31,
		2014			2013
	Deferred tax asset for NOL carryforwards	$	10,649,000		$	5,144,000
	Deferred tax liability for intangibles		(165,000	)		(165,000	)
	Share based compensation		4,205,000			3,683,000
	Non deductible accrued expenses		—			150,000
	Valuation allowance		(14,689,000	)		(8,812,000	)
		$	—		$	—

WARRANT_LIABILITY_Tables

WARRANT LIABILITY (Tables)	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
NOTES PAYABLE	NOTE 8 – NOTES PAYABLE
	During the fourth quarter of 2013, all of the $561,000 of unsecured notes payable, less 9,914 of unamortized discount, plus accrued interest of $83,715 was converted into 4,473,333 shares of common stock plus a cash repayment of $150,000. Since this conversion was with a related party it was treated as a capital transaction in accordance with FASB ASC 470-50-40-3.
	Private Placement of 8% Series A Notes Payable
	In August 2009, the Company commenced a private placement of up to $300,000 consisting of up to 6 units. Each unit consists of a $50,000, 8% Series A Note Payable, due September 30, 2011, and a non-detachable warrant to purchase 2 million shares of the Company’s common stock. During 2009, the Company sold 4 units, issued $200,000 of 8% Series A Notes Payable, issued 8 million warrants, and raised $180,000, net of commission of $20,000. In January 2010, the Company sold .5 units, issued $25,000 of 8% Series A Notes Payable, issued 1 million warrants, and raised $17,500 net of commissions of $7,500. The commissions were treated as deferred finance charges and fully expensed over the term of notes payable.
	The 8 million warrants in 2009 were valued at $15,450, fair value, using the Black-Scholes option pricing model to calculate the fair-value of the warrants, with the following assumptions: no dividend yield, expected volatility of between 30.9% and 34.5%, risk free interest rate between .95% and 1.06% and warrant life of approximately 2 years. The 1 million warrants in 2010 were valued at $20,143, fair value, using the Black-Scholes option pricing model to calculate the fair-value of the warrants, with the following assumptions: no dividend yield, expected volatility of 28.6 %, risk free interest rate of .84% and warrant life of approximately 2 years.
	In June 2011, the maturity date on the $150,000 of the 8% Series A Notes Payable and the term on the associated 6 million warrants were extended to September 30, 2015. As a result, the warrants were revalued using the Black-Scholes option pricing model to calculate the incremental fair-value of the warrants of $21,275, with the following assumptions: no dividend yield, expected volatility of 60%, risk free interest rate of 1.52% and warrant life of approximately 1.25 years. As part of the debt extension, the lender holding the 6 million warrants agreed in writing to suspend its right to exercise these warrants until such time that the Company’s authorized shares have been increased. The authorized shares of the Company’s common stock were increased on May 23, 2013 from 425,000,000 to 675,000,000.
	The relative fair value of the warrants issued in conjunction with the 8% Series A Notes Payable have been treated as a debt discount with an offsetting credit to additional paid-in capital. The debt discount related to the warrant issuances is being accreted to interest expense over the term of the notes. When the warrants were revalued the incremental amount of $21,275 was also treated as additional debt discount and is being accreted over the new term of the 8% Series A Notes Payable. As of December 31, 2012 the unaccreted debt discount related to warrants issued in conjunction with the 8% Series A Notes payable was $13,632.
	During the third quarter of 2011, $25,000 plus accrued interest of the 8% Series A Notes Payable were repaid and 3 million of the associated warrants expired unexercised.
	During the fourth quarter of 2013, the remaining series A notes payable of $150,000 was reduced by $60,000 for the exercise of 6,000,000 warrants into 6,000,000 shares of common stock. The balance of $90,000 plus accrued interest of $49,000 was converted into 1,226,363 shares of common stock. Since this conversion was with a related party it was treated as a capital transaction in accordance with FASB ASC 470-50-40-3.
	Private Placement of 25% Notes Payable
	In 2010, the Company issued $400,000 in notes payable in order to finance a patent infringement lawsuit (see Note 15 - Contingencies to these consolidated financial statements). The notes payable accrue interest at 25% per annum and mature upon the earlier of September 1, 2013 or the date on which the Company receives net proceeds from the patent infringement claim. In addition to the base interest of 25% per annum, the lenders are entitled to Bonus Interest equal to the following:
		a.	First monies realized by the Company from its share of the net proceeds of the lawsuit shall be allocated and paid to the Lender until the principal and base interest accruing has been fully paid.
		b.	The next monies from the net proceeds of the litigation settlement will be paid to the Company to reimburse for out-of-pocket legal costs related to the lawsuit.
		c.	The next $825,000 of proceeds will be split 50%/50% between the Company and the Lenders.
		d.	The next $1 million realized by the Company shall be allocated 90% to the Company and 10% to the Lenders.
		e.	The next $1 million realized by Company shall be allocated 85% to Company and 15% to Lenders.
		f.	All remaining proceeds realized by Company shall be allocated 80% to Company and 20% to Lenders.
	The Lenders have a security interest in the Company’s patent infringement claim in which the Lender has the right to the net proceeds of this lawsuit to satisfy outstanding principal and interest under the notes.
	As part of the private placement of the 25% notes payable, the Company incurred debt placement fees of $34,500 in 2010. These debt placement fees have been treated as deferred finance charges and were being amortized to interest expense over two years. The remainder of amortization $13,625 was recorded the years ended December 31, 2012.
	In December 2012, 250,000 of these notes payable and accrued interest of $122,397 were converted into 8,219,911 shares of the Company’s common stock. In March 2013, the remaining $150,000 of the notes payable and accrued interest of $70,000 were converted into 3 million shares of the Company’s common stock. Accrued interest of $13,895 was paid in cash.
	Notes payable consists of the following as of December 31:
			December 31,			December 31,
			2014			2013
	Unsecured notes payable due to related parties; interest at 10% per annum; principal and accrued interest due at maturity in September 2015		$	114,000		$	330,249
	Series A notes payable; interest at 8% per annum; principal and accrued interest due at maturity in October 2011 (past due)			50,000			50,000
	Notes payable; interest at 8% per annum; principal and accrued interest due at December 1, 2014 (past due)			650,000			—
	Notes payable, interest at 5% and 8% per annum; principal and interest due April 2015			123,000			—
	Less: Debt discount			(10,447	)		—
				926,553			380,249
	Less: Current portion			926,553			50,000
	Long-term portion		$	—		$	330,249
	At December 31, 2014 and 2013 accrued interest on notes payable was $155,992 and $317,344.
	The notes payable balance as of December 31, 2014 includes a Series A note payable in the amount of $50,000 with interest of 8% per annum. This note matured in October 2011 and is past due. Accrued interest associated with this note was $20,667 as of December 31, 2014. The Company has been unable to locate this shareholder.
	On June 10, 2014, the Company issued a note payable for $250,000, which included fully vested warrants to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.10 per share, expiring in five years. The warrants were valued at $39,650 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 248.2%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $34,222 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition, and is being accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $34,222 was accreted through interest expense. The note and accrued interest at 8% per annum was originally due on December 11, 2014, but the Company received approval to extend the maturity until December 31, 2014. As of December 31, 2014 the note is in default. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of December 31, 2014, the fair value of the warrant liability was $17,741 and the note payable balance was $250,000. This note is in default.
	On August 5, 2014, the Company issued notes payable for $100,000, which included fully vested warrants to purchase 600,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $29,725 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $22,914 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition, and is being accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $22,914 was accreted through interest expense. The note and accrued interest at 8% per annum were due in full on December 1, 2014. As of December 31, 2014 the note is in default. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of December 31, 2014, the fair value of the warrant liability was $11,178 and the note payable balance was $100,000. This note is in default.
	On August 12, 2014, the Company issued notes payable for $50,000, which included fully vested warrants to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $26,817 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $17,455 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition, and is being accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $17,455 was accreted through interest expense. The note and accrued interest at 8% per annum were due in full on December 1, 2014. As of December 31, 2014 the note is in default. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of December 31, 2014, the fair value of the warrant liability was $5,585 and the note payable balance was $50,000. This note is in default.
	On August 14, 2014, the Company issued notes payable for $100,000, which included fully vested warrants to purchase 600,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $47,676 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $32,274 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition, and is being accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $32,274 was accreted through interest expense. The note and accrued interest at 8% per annum were due in full on December 1, 2014. As of December 31, 2014 the note is in default. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of December 31, 2014, the fair value of the warrant liability was $11,226 and the note payable balance was $100,000. This note is in default.
	On September 8, 2014, the Company issued notes payable for $150,000, which included fully vested warrants to purchase 900,000 shares of the Company’s common stock at an exercise price of $0.05 per share, expiring in five years. The warrants were valued at $62,544 using Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 233.8%, risk free interest rate of 1.67% and expected life of 5 years. The relative fair value of the warrants was $44,140 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition, and is being accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $44,140 was accreted through interest expense. The note and accrued interest at 8% per annum were due in full on December 1, 2014. As of December 31, 2014 the notes are in default. The warrants are subject to anti-dilutive adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is re-valued at each reporting period with the change in fair value recorded through earnings. As of December 31, 2014, the fair value of the warrant liability was $17,385 and the note payable balance was $150,000. This note is in default.
	On December 5, 2014, the Company issued a note payable for $23,000 to a stockholder, which bears interest at 5.0% and is due on April 5, 2015. This note is in default.
	On December 31, 2014, the Company issued a note payable for $100,000, which include fully vested warrants to purchase 600,000 shares of the Company’s common stock at an exercise price of $0.05 per share expiring in five years. The warrants were valued at $11,812 using the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants, with the following assumptions: no dividend yield, expected volatility of 229.0%, risk free interest rate of 1.68% and expected life of 5 years. The relative fair value of the warrants was $10,563 and was recorded as a discount to the notes payable in accordance with FASB ASC 835-30-25, Recognition, and is being accreted over the term of the note payable for financial statement purposes. For the year ended December 31, 2014, $116 was accreted through interest expense. The note and accrued interest at 8% per annum were due in full on April 1, 2015. This note is currently in default. The warrants are subject to anti-dilution adjustments and are therefore classified as a liability in accordance with FASB ASC 815. The warrant liability is revalued at each reporting period with the change in fair value recorded through earnings. As of December 31, 2014, the fair value of the warrant liability was $11,812 and the note payable balance was $89,553, net of a discount of $10,447. This note is in default.

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of notes payable	Notes payable consists of the following as of December 31:
		December 31,			December 31,
		2014			2013
	Unsecured notes payable due to related parties; interest at 10% per annum; principal and accrued interest due at maturity in September 2015	$	114,000		$	330,249
	Series A notes payable; interest at 8% per annum; principal and accrued interest due at maturity in October 2011 (past due)		50,000			50,000
	Notes payable; interest at 8% per annum; principal and accrued interest due at December 1, 2014 (past due)		650,000			—
	Notes payable, interest at 5% and 8% per annum; principal and interest due April 2015		123,000			—
	Less: Debt discount		(10,447	)		—
			926,553			380,249
	Less: Current portion		926,553			50,000
	Long-term portion	$	—		$	330,249

FAIR_VALUE_OF_FINANCIAL_INSTRU1

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Schedule of Liabilities Measured at Fair Value on a Recurring Basis	Liabilities measured at fair value on a recurring basis are summarized as follows:
		Level 1			Level 2		Level 3		Total
	Derivative liability related to fair value of beneficial conversion feature	$	—		$	—	$	—	$	—
	Derivative liability related to fair value of warrants		—			—		6,370,709		6,370,709
	Total	$	—		$	—	$	6,370,709	$	6,370,709
Fair Value Measurements within the Fair Value Hierarchy of Derivative Liabilities Using Level 3 Inputs	The following table details the approximate fair value measurements within the fair value hierarchy of the Company’s derivative liabilities using Level 3 inputs:
		Total
	Balance at January 1, 2014	$	6,000,000
	Additional Warrants issued January 2014		444,000
	Additional Warrants issued June 2014		34,222
	Additional Warrants issued 3rd Quarter 2014		166,791
	Additional Warrants Issued 4th Quarter 2014		4,903,900
	Change in fair value of derivative liabilities		(5,178,204	)
	Balance at December 31, 2014	$	6,370,709
Embedded Derivative Liability Valuation Assumptions	The Preferred Stock shares are convertible into shares of the Company’s common stock, which did traded in an active securities market, therefore the embedded derivative liability was valued using the following market based inputs:
	Closing trade price of Common Stock	$	0.02
	Series A Preferred Stock Conversion price	$	0.03
	Intrinsic value of conversion option per share	$	—
Schedule of Common Stock Purchase Warrants Valuation Assumptions	As of December 31, 2014, the Company’s outstanding warrants were treated as derivative liabilities and changes in the fair value were recognized in earnings. These common stock purchase warrants did not trade in an active securities market, and as such, the Company estimated the fair value of these warrants using Black-Scholes and the following assumptions:
		December 31, 2014
	Annual Dividend Yield		0.00%
	Expected Life (Years)		3.0 - 4.69
	Risk-Free Interest Rate		1.10% -1.65%
	Expected Volatility		174.8% - 203.6%

STOCK_OPTIONS_Tables

STOCK OPTIONS (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Non-employee Stock Option/Warrant Activity	The following tables summarize non-employee stock option/warrant activity of the Company since December 31, 2012:
							Weighted Average
		Option/Warrant			Exercise		Exercise
		Shares			Price		Price
	Outstanding, December 31, 2012		82,807,221		$	0.00125 to $0.20	$	0.01
	Granted		38,144,444			0.10 - 0.15		0.03
	Exercised		(9,435,000	)		0.00125 - 0.07		—
	Expired		—			—		—
	Outstanding, December 31, 2013		111,516,665			0.00125 to 0.20		0.09
	Granted		10,349,209			0.05 - 0.10		0.01
	Exercised		—			—		—
	Expired		(700,000	)		—		—
	*Outstanding, December 31, 2014		121,165,874		$	0.01 to $.20	$	0.1
	*Exercisable, December 31, 2014		121,165,874		$	0.01 to $.20	$	0.1
	Weighted Average Remaining Life, Exercisable, December 31, 2014 (years)		5.7
	* Does not include 250,000,000 warrants that are due to be issued on January 1, 2015. The warrants has a fair value of $4,892,089 and are reflected in warrant liabilities on the balance sheet as of December 31, 2014 and the corresponding expense is reflected in research and development expense.
Schedule of Incentive Stock Option Transactions for Employees	A summary of incentive stock option transactions for employees since December 31, 2013 is as follows:
		Option/Warrant			Exercise Price		Weighted Average
		Shares					Exercise Price
	Outstanding, December 31, 2012		15,766,667		$	0.00125 to $0.10	$	0.06
	Granted		45,500,000			0.05 - 0.15		0.04
	Exercised		(900,000	)		0.00125		—
	Expired		(500,000	)		0.05		—
	Outstanding, December 31, 2013		59,866,667			0.00125 to 0.15		0.06
	Granted		6,000,000			0.05		0.01
	Exercised		(12,000,000	)		0.05		0.01
	Expired		—			—		—
	Outstanding, December 31, 2014		53,866,667		$	0.05 - $0.15	$	0.05
	Exercisable, December 31, 2014		51,366,667		$	0.05 - $0.15	$	0.06
	Weighted Average Remaining Life, Exercisable, December 31, 2014 (years)		8.3

OPERATING_LEASES_Tables

OPERATING LEASES (Tables)	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
Schedule of Non-cancelable Operating Lease Arrangements for Property	At December 31, 2014, the Company was obligated under various non-cancelable operating lease arrangements for property as follows:
	2015		74,637
	2016		31,605
		$	106,242

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Textuals) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
	Segment
	Institution
Schedule Of Significant Accounting Policies [Line Items]
Number of financial institutions at which company's cash and cash equivalents are held	2
Depreciation method of property and equipment	Straight-line method
Research and development costs	$10,590,271	$655,840
Number of operating segment	1
Patents and Trademark
Schedule Of Significant Accounting Policies [Line Items]
Number of provisional patents filed	11
Number of patents issued	7
Amortization method of patents	Straight-line basis
Patents and Trademark | UNITED STATES
Schedule Of Significant Accounting Policies [Line Items]
Number of provisional patents pending for allowance.	4
Patents and Trademark | Foreign Countries
Schedule Of Significant Accounting Policies [Line Items]
Number of provisional patents pending for allowance.	5
Sales and marketing expenses
Schedule Of Significant Accounting Policies [Line Items]
Advertising costs	$62,835	$53,979
Minimum
Schedule Of Significant Accounting Policies [Line Items]
Estimated useful lives of property and equipment	5 years
Minimum | Patents and Trademark
Schedule Of Significant Accounting Policies [Line Items]
Estimated lives of patents	17 years
Maximum
Schedule Of Significant Accounting Policies [Line Items]
Estimated useful lives of property and equipment	7 years
Maximum | Patents and Trademark
Schedule Of Significant Accounting Policies [Line Items]
Estimated lives of patents	20 years

PROPERTY_AND_EQUIPMENT_Detail

PROPERTY AND EQUIPMENT (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment, Net [Abstract]
Furniture and Fixtures	$219,871	$219,871
Equipment	16,155	16,155
Property, Plant and Equipment, Gross, Total	236,026	236,026
Less: Accumulated depreciation	161,205	91,952
Capital equipment, net of accumulated depreciation of $161,205 and $91,952 as of December 31, 2014 and 2013	$74,821	$144,074

PROPERTY_AND_EQUIPMENT_Textual

PROPERTY AND EQUIPMENT (Textuals) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment, Net [Abstract]
Depreciation of property and equipment	$69,253	$68,839

PATENTS_AND_TRADEMARK_Textuals

PATENTS AND TRADEMARK (Textuals) (Detail) (Patents and Trademark, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
	Patents
Finite-Lived Intangible Assets [Line Items]
Number of patents issued	7
Amortization method of patents	Straight-line basis
Capitalized patent costs	$0	$21,954
UNITED STATES
Finite-Lived Intangible Assets [Line Items]
Number of provisional patents pending for allowance	4
Foreign Countries
Finite-Lived Intangible Assets [Line Items]
Number of provisional patents pending for allowance	5
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated lives of patents	17 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated lives of patents	20 years

INCOME_TAX_Textuals_Detail

INCOME TAX (Textuals) (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Net operating loss ("NOL")	$26
Federal Statutory Rate	-35.00%	-35.00%

INCOME_TAX_BENEFIT_PROVISION_D

INCOME TAX BENEFIT (PROVISION) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Current	($5,505,000)	$1,837,000
Deferred	-372,000	3,284,000
Change in valuation allowance	5,877,000	-5,121,000
INCOME TAX BENEFIT	$0	$0

RECONCILIATION_OF_TAX_DERIVED_

RECONCILIATION OF TAX DERIVED BY APPLYING U.S. FEDERAL STATUTORY RATE (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, Amount [Abstract]
U.S federal income tax benefit at federal statutory rate	($2,771,000)	($5,718,000)
State tax, net of federal tax effect	-463,000	-956,000
Deductible share based compensation		-318,000
Non-deductible changes in derviative liability and share based transactions	-2,639,000	1,895,000
Other	-4,000	-24,000
Change in valuation allowance	5,877,000	5,121,000
INCOME TAX BENEFIT	$0	$0
U.S federal income tax benefit at federal statutory rate	-35.00%	-35.00%
State tax, net of federal tax effect	-6.00%	-6.00%
Deductible share based compensation		-2.00%
Non-deductible changes in derviative liability and share based transactions	-33.00%	12.00%
Other	0.00%	0.00%
Change in valuation allowance	74.00%	31.00%
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%	0.00%

PRIMARY_COMPONENTS_OF_ASSETS_L

PRIMARY COMPONENTS OF ASSETS, LIABILITIES AND RELATED VALUATION ALLOWANCE (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred Tax Assets, Net, Classification [Abstract]
Deferred tax asset for NOL carryforwards	$10,649,000	$5,144,000
Deferred tax liability for intangibles	-165,000	-165,000
Share based compensation	4,205,000	3,683,000
Non deductible accrued expenses		150,000
Valuation allowance	-14,689,000	-8,812,000
Deferred Tax Assets, Net, Total	$0	$0

SENIOR_SECURED_CONVERTIBLE_NOT1

SENIOR SECURED CONVERTIBLE NOTES PAYABLE (Detail Textuals) (Detail) (USD $)	12 Months Ended	1 Months Ended	3 Months Ended			12 Months Ended
	Dec. 31, 2013	Jun. 30, 2013	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2006	Dec. 31, 2014	Jun. 30, 2011	31-May-07	Feb. 28, 2006
Debt Instrument [Line Items]
Accrued interest	$300,677			$300,677			$112,885
Common stock shares issued on conversion of debt (in shares)	1,890,000
10% Senior Secured Convertible Promissory Notes
Debt Instrument [Line Items]
Debt instrument principal amount	220,000	225,000		220,000				596,500		800,000
Interest rate								10.00%	12.00%	10.00%
Sale price of notes payable						800,000
Remaining debt and accrued interest was extended until September 15, 2015					178,749
Accrued interest	395,000	181,125		395,000
Common stock shares issued on conversion of debt (in shares)		7,400,000	8,448,519	7,900,000
Amount of notes converted in to common stock shares		$1,628,000	$216,249

SENIOR_SECURED_CONVERTIBLE_NOT2

SENIOR SECURED CONVERTIBLE NOTES PAYABLE (Textuals) (Detail) (USD $)	12 Months Ended		1 Months Ended	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jun. 30, 2013	Jun. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Common stock shares issued on conversion of debt (in shares)		1,890,000
Gains (Losses) on Extinguishment of Debt	($82,000)	($1,221,875)
Outstanding principal balance on notes	114,000	330,249			330,249
Accrued interest	112,885	300,677			300,677
10% Senior Secured Convertible Promissory Notes
Debt Instrument [Line Items]
Amount of notes converted into common stock shares			1,628,000	216,249
Accrued interest of notes converted into common stock shares				208,339
Common stock shares issued on conversion of debt (in shares)			7,400,000	8,448,519	7,900,000
Gains (Losses) on Extinguishment of Debt				-82,000
Accrued interest		$395,000	$181,125		$395,000
Debt instrument conditional covenants amount	If an equity financing with total proceeds of more than $5,000,000 occurs while any of these notes are outstanding, holders of notes will have the right, at their option, to convert the outstanding principal and interest of the notes into shares of common stock at a discount of 30% of the price per share in the qualified financing.
Percentage of discount on price per share	30.00%

CONVERTIBLE_NOTES_PAYABLE_Deta

CONVERTIBLE NOTES PAYABLE (Detail Textuals) (Detail) (USD $)	12 Months Ended		1 Months Ended	3 Months Ended	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2009	Dec. 31, 2013	Dec. 31, 2008	Dec. 31, 2007	Mar. 19, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Proceeds from issuance of notes payable	$798,000
Convertible notes payable							126,000	140,000
Common stock shares issued on conversion of debt (in shares)		1,890,000
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt instrument principal amount						400,000
Interest rate			10.00%			10.00%
Maturity date			2015-09			2008-08
Proceeds from issuance of notes payable					25,000	375,000
Amount of notes converted in to common stock shares			260,000			260,000
Number of common stock shares issued on conversion of notes			48,750,000
Initial conversion price per share (in dollars per share)					$0.01
Convertible notes payable		98,000	140,000	98,000
Common stock shares issued on conversion of debt (in shares)				12,375,000
Warrants issued			26,250,000
Accrued interest		87,150		87,150
Beneficial conversion feature related to the issuance of convertible notes payable					25,000	375,000
Common stock issuance price per share for convertible notes payable (in dollars per share)						$0.02
Convertible Notes Payable [Member] | Vice Chairman [Member]
Debt Instrument [Line Items]
Convertible notes payable							14,000
Common stock shares issued on conversion of debt (in shares)							2,625,000
Convertible Notes Payable [Member] | Accredited Investor
Debt Instrument [Line Items]
Convertible notes payable							$28,000
Common stock shares issued on conversion of debt (in shares)							5,250,000
Convertible Notes Payable [Member] | Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Initial conversion price per share (in dollars per share)						$0.01

NOTES_PAYABLE_Summary_of_notes

NOTES PAYABLE - Summary of notes payable (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Less: Debt discount	($10,447)
Notes payable	926,553	380,249
Less: Current portion	812,553	50,000
Long-term portion		330,249
Adjustment
Debt Instrument [Line Items]
Less: Current portion	926,553
Unsecured notes payable due to related parties; interest at 10% per annum; principal and accrued interest due at maturity in September 2015
Debt Instrument [Line Items]
Notes payable	114,000	330,249
Series A notes payable; interest at 8% per annum; principal and accrued interest due at maturity in October 2011 (past due)
Debt Instrument [Line Items]
Notes payable	50,000	50,000
Notes payable; interest at 8% per annum; principal and accrued interest due at December 1, 2014 (past due)
Debt Instrument [Line Items]
Notes payable	650,000
Notes payable, interest at 5% and 8% per annum; principal and interest due April 2015
Debt Instrument [Line Items]
Notes payable	$123,000

NOTES_PAYABLE_Summary_of_notes1

NOTES PAYABLE - Summary of notes payable (Parenthetical) (Detail)	Dec. 31, 2014	Dec. 31, 2013
Unsecured notes payable due to related parties; interest at 10% per annum; principal and accrued interest due at maturity in September 2015
Debt Instrument [Line Items]
Interest rate	10.00%	10.00%
Series A notes payable; interest at 8% per annum; principal and accrued interest due at maturity in October 2011 (past due)
Debt Instrument [Line Items]
Interest rate	8.00%	8.00%
Notes payable; interest at 8% per annum; principal and accrued interest due at December 1, 2014 (past due)
Debt Instrument [Line Items]
Interest rate	8.00%
Notes payable, interest at 5% and 8% per annum; principal and interest due April 2015
Debt Instrument [Line Items]
Interest rate	5.00%	8.00%

NOTES_PAYABLE_Textuals_Detail

NOTES PAYABLE (Textuals) (Detail) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jun. 10, 2014	Aug. 05, 2014	Aug. 12, 2014	Aug. 14, 2014	Sep. 08, 2014	Dec. 05, 2014
Debt Instrument [Line Items]
Note payable balance	$812,553	$50,000
Proceeds from issuance of notes payable	798,000
Accumulated discount, notes payable (in dollars)	10,447
Interest expense	199,364	127,825
Warrant | June 10, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	17,741
Warrant | August 5, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	11,178
Warrant | August 12, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	5,585
Warrant | August 14, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	11,226
Warrant | September 8, 2014
Debt Instrument [Line Items]
Fair value of warrant liability	17,385
Warrant | Debt Instrument Date December 2014
Debt Instrument [Line Items]
Fair value of warrant liability	11,812
Series A Notes Payable
Debt Instrument [Line Items]
Note payable balance	50,000
Interest rate, notes payable	8.00%
Accrued interest	20,667
Notes Payable
Debt Instrument [Line Items]
Accrued interest	155,992	317,344
Notes Payable | June 10, 2014
Debt Instrument [Line Items]
Note payable balance	250,000
Interest rate, notes payable	8.00%
Interest expense	34,222
Notes Payable | August 5, 2014
Debt Instrument [Line Items]
Note payable balance	100,000
Interest rate, notes payable	8.00%
Interest expense	22,914
Notes Payable | August 12, 2014
Debt Instrument [Line Items]
Note payable balance	50,000
Interest rate, notes payable	8.00%
Interest expense	17,455
Notes Payable | August 14, 2014
Debt Instrument [Line Items]
Note payable balance	100,000
Interest rate, notes payable	8.00%
Interest expense	32,274
Notes Payable | September 8, 2014
Debt Instrument [Line Items]
Note payable balance	150,000
Interest rate, notes payable	8.00%
Interest expense	44,140
Notes Payable | Debt Instrument Date December 2014
Debt Instrument [Line Items]
Note payable balance	89,553
Interest rate, notes payable	8.00%
Interest expense	116
Notes Payable | Warrant | June 10, 2014
Debt Instrument [Line Items]
Proceeds from issuance of notes payable			250,000
Number of common stock called by warrants (in shares)			1,000,000
Exercise price (in dollars per share)			$0.10
Fair value of warrant liability			39,650
Expected volatility			248.20%
Risk-free interest rate			1.67%
Expected warrant term			5 years
Accumulated discount, notes payable (in dollars)			34,222
Notes Payable | Warrant | August 5, 2014
Debt Instrument [Line Items]
Proceeds from issuance of notes payable				100,000
Number of common stock called by warrants (in shares)				600,000
Exercise price (in dollars per share)				$0.05
Fair value of warrant liability				29,725
Expected volatility				233.80%
Risk-free interest rate				1.67%
Expected warrant term				5 years
Accumulated discount, notes payable (in dollars)				22,914
Notes Payable | Warrant | August 12, 2014
Debt Instrument [Line Items]
Proceeds from issuance of notes payable					50,000
Number of common stock called by warrants (in shares)					300,000
Exercise price (in dollars per share)					$0.05
Fair value of warrant liability					26,817
Expected volatility					233.80%
Risk-free interest rate					1.67%
Expected warrant term					5 years
Accumulated discount, notes payable (in dollars)					17,455
Notes Payable | Warrant | August 14, 2014
Debt Instrument [Line Items]
Proceeds from issuance of notes payable						100,000
Number of common stock called by warrants (in shares)						600,000
Exercise price (in dollars per share)						$0.05
Fair value of warrant liability						47,676
Expected volatility						233.80%
Risk-free interest rate						1.67%
Expected warrant term						5 years
Accumulated discount, notes payable (in dollars)						32,274
Notes Payable | Warrant | September 8, 2014
Debt Instrument [Line Items]
Proceeds from issuance of notes payable							150,000
Number of common stock called by warrants (in shares)							900,000
Exercise price (in dollars per share)							$0.05
Fair value of warrant liability							62,544
Expected volatility							233.80%
Risk-free interest rate							1.67%
Expected warrant term							5 years
Accumulated discount, notes payable (in dollars)							44,140
Notes Payable | Warrant | Debt Instrument Date December 2014
Debt Instrument [Line Items]
Proceeds from issuance of notes payable	100,000
Number of common stock called by warrants (in shares)	600,000
Exercise price (in dollars per share)	$0.05
Fair value of warrant liability	11,812
Expected volatility	229.00%
Risk-free interest rate	1.68%
Expected warrant term	5 years
Accumulated discount, notes payable (in dollars)	10,447
Notes Payable | Warrant | Debt Instrument Date December 2014 | During the issuance
Debt Instrument [Line Items]
Accumulated discount, notes payable (in dollars)	10,563
Notes Payable | Stockholder
Debt Instrument [Line Items]
Interest rate, notes payable								5.00%
Proceeds from issuance of notes payable								$23,000
Note due date								5-Apr-15

NOTES_PAYABLE_Detail_Textuals_

NOTES PAYABLE (Detail Textuals) (Detail) (USD $)	12 Months Ended	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2014
Debt Instrument [Line Items]
Amount of unamortized discount			$10,447
Number of shares issued upon conversion of debt	1,890,000
Amount of cash repaid	150,000
Unsecured notes payable due to related parties; interest at 10% per annum; principal and accrued interest due at maturity in September 2015
Debt Instrument [Line Items]
Amount of note payable	561,000	561,000
Amount of unamortized discount	9,914	9,914
Accrued interest	83,715	83,715
Number of shares issued upon conversion of debt		4,473,333
Amount of cash repaid		$150,000

NOTES_PAYABLE_Detail_Textuals_1

NOTES PAYABLE (Detail Textuals 2) (Detail) (USD $)	1 Months Ended	12 Months Ended
	Jan. 31, 2010	Dec. 31, 2009	Mar. 19, 2013	Dec. 31, 2012	Sep. 30, 2011	Aug. 31, 2009
	Unit	Unit				Unit
Debt Instrument [Line Items]
Convertible notes payable			$126,000	$140,000
8% Series A Notes Payable
Debt Instrument [Line Items]
Convertible notes payable	25,000	200,000			50,000	300,000
Number of units	0.5	4				6
Interest rate	8.00%	8.00%			8.00%
Number of shares of common stock					2,000,000
Warrants issued	1,000,000	8,000,000
Proceeds from issuance of units	17,500	180,000
Commissions charges	$7,500	$20,000

NOTES_PAYABLE_Detail_Textuals_2

NOTES PAYABLE (Detail Textuals 3) (Detail) (USD $)	12 Months Ended	3 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Jun. 30, 2011	Dec. 31, 2009	Jan. 31, 2010	Sep. 30, 2011	Dec. 31, 2010	Dec. 31, 2014	23-May-13	22-May-13	Dec. 31, 2012
Debt Instrument [Line Items]
Common stock, shares authorized	675,000,000	675,000,000						675,000,000
Discount, notes payable (in dollars)								$10,447
Number of shares issued upon conversion of debt	1,890,000
Common Stock
Debt Instrument [Line Items]
Number of shares issued upon conversion of debt	18,275	25,974,697
Series A notes payable; interest at 8% per annum; principal and accrued interest due at extended maturity date in September 2015
Debt Instrument [Line Items]
Warrants issued			6,000,000
Amount of note payable			150,000
Interest rate			8.00%
Common stock, shares authorized									675,000,000	425,000,000
Series A notes payable; interest at 8% per annum; principal and accrued interest due at extended maturity date in September 2015 | Warrant
Debt Instrument [Line Items]
Warrants issued				8,000,000
Fair value of the warrants			21,275	15,450
Method used to calculate fair value of warrants			Black-Scholes option pricing model	Black-Scholes option pricing model
Dividend yield			0.00%	0.00%
Expected volatility			60.00%
Risk-free interest rate			1.52%
Expected warrant term			1 year 3 months	2 years
Series A notes payable; interest at 8% per annum; principal and accrued interest due at extended maturity date in September 2015 | Warrant | Minimum
Debt Instrument [Line Items]
Expected volatility				30.90%
Risk-free interest rate				0.95%
Series A notes payable; interest at 8% per annum; principal and accrued interest due at extended maturity date in September 2015 | Warrant | Maximum
Debt Instrument [Line Items]
Expected volatility				34.50%
Risk-free interest rate				1.06%
8% Series A Notes Payable
Debt Instrument [Line Items]
Warrants issued				8,000,000	1,000,000
Amount of note payable	150,000	150,000
Interest rate				8.00%	8.00%	8.00%
Discount, notes payable (in dollars)											13,632
Amount of notes payable repaid with accrued interest						25,000
Number of warrants expired unexercised						3,000,000
Reduction in value of debt		60,000
Number of warrants exercised for conversion of securities		6,000,000
Balance amount of debt		90,000
Amount of accrued interest	49,000	49,000
Number of common stock called by warrants (in shares)						2,000,000
8% Series A Notes Payable | Common Stock
Debt Instrument [Line Items]
Number of common stock called by warrants (in shares)	6,000,000	6,000,000
Number of shares issued upon conversion of debt		1,226,363
8% Series A Notes Payable | Warrant
Debt Instrument [Line Items]
Warrants issued							1,000,000
Fair value of the warrants							$20,143
Method used to calculate fair value of warrants							Black-Scholes option pricing model
Dividend yield							0.00%
Expected volatility							28.60%
Risk-free interest rate							0.84%
Expected warrant term							2 years

NOTES_PAYABLE_Detail_Textuals_3

NOTES PAYABLE (Detail Textuals 4) (Detail) (Private Placement of 25% Notes Payable, USD $)	Dec. 31, 2010
Private Placement of 25% Notes Payable
Debt Instrument [Line Items]
Note payable, amount	$400,000
Interest rate	25.00%

NOTES_PAYABLE_Detail_Textuals_4

NOTES PAYABLE (Detail Textuals 5) (Detail) (Private Placement of 25% Notes Payable, USD $)	12 Months Ended
	Dec. 31, 2010
Litigation Case Three [Member]
Debt Instrument [Line Items]
Proceeds from litigation settlement	$825,000
Percentage allocated to company	50.00%
Percentage allocated to lenders	50.00%
Litigation Case Four [Member]
Debt Instrument [Line Items]
Proceeds from litigation settlement	1,000,000
Percentage allocated to company	90.00%
Percentage allocated to lenders	10.00%
Litigation Case Five [Member]
Debt Instrument [Line Items]
Proceeds from litigation settlement	$1,000,000
Percentage allocated to company	85.00%
Percentage allocated to lenders	15.00%
Litigation Case Six [Member]
Debt Instrument [Line Items]
Percentage allocated to company	80.00%
Percentage allocated to lenders	20.00%

NOTES_PAYABLE_Detail_Textuals_5

NOTES PAYABLE (Detail Textuals 6) (Detail) (USD $)	12 Months Ended	1 Months Ended	12 Months Ended
	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2014
Debt Instrument [Line Items]
Accrued interest paid in cash	$13,895
Number of shares issued upon conversion of debt	1,890,000
Private Placement of 25% Notes Payable
Debt Instrument [Line Items]
Interest rate				25.00%
Debt placement fees				34,500
Amortization of deferred finance charges			13,625
Private placement of convertible notes		150,000	250,000
Accrued interest		70,000	122,397
Accrued interest paid in cash			13,895
Number of shares issued upon conversion of debt		3,000,000	8,219,911
Notes Payable
Debt Instrument [Line Items]
Accrued interest	$317,344				$155,992

WARRANT_LIABILITY_Detail

WARRANT LIABILITY (Detail) (USD $)	0 Months Ended	12 Months Ended
	Jan. 02, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Major Agreements [Line Items]
Warrant liability		$6,370,709	$6,000,000
Current share price (in dollars per share)		$0.02
Verify Me | Warrants issued on January 1, 2014
Major Agreements [Line Items]
Fair value of warrant liability		121,209
Number of warrants issued	6,349,206
Exercise price (in dollars per share)	$0.10
Agreements | Zaah Technologies
Major Agreements [Line Items]
Warrant liability				2,400,000
Fair value of warrant liability		787,544	3,700,000
Agreements | Verify Me | Research and Development Expense
Major Agreements [Line Items]
Initial fair value of warrant expensed as research and development cost	444,000
Patent And Technology Agreement
Major Agreements [Line Items]
Exercise price (in dollars per share)		$0.10
Additional payment for patent and technology		4,500,000
Discount to market price at time of issuance		10.00%
Current share price (in dollars per share)		$0.04
Additional shares issued for patent and technology agreement (in shares)		125,000,000
Number of common stock shares purchased under warrants (in shares)		125,000,000
Patent And Technology Agreement | Stock Options And Warrants
Major Agreements [Line Items]
Number of warrants to be issued(in shares)		250,000,000
Exercise price of warrant to be issued(in dollars per share)		$0.02
Warrant to be issued value		$4,892,089
Patent And Technology Agreement | Stock Options And Warrants | Warrant
Major Agreements [Line Items]
Dividend yield		0.00%
Expected volatility		229.10%
Risk free interest		1.65%
Expected warrant term		5 years
Patent And Technology Agreement | Verify Me
Major Agreements [Line Items]
Additional shares issued for patent and technology agreement (in shares)		6,349,206

CONVERTIBLE_PREFERRED_STOCK_De

CONVERTIBLE PREFERRED STOCK (Detail) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Jan. 31, 2013	Aug. 31, 2013
Class of Stock [Line Items]
Preferred stock value	$633,333	$633,333	$633,333
Fair value of warrants	494,939	2,300,000
Common Stock
Class of Stock [Line Items]
Number of preferred stock purchased		4,811,111
Subscription Agreement
Class of Stock [Line Items]
Convertible preferred stock description			At any time before January 31, 2015, VerifyMe has the right, but not the obligation, to require the Company to repurchase all, but not less than all, of the capital stock of the Company and warrants exercisable for capital stock of the Company held by VerifyMe in exchange for the price originally paid by VerifyMe therefor upon the occurrence of any of the following events:(i) the consummation of any bona fide business acquisition, (ii) the incurrence of any indebtedness by the Company in an amount in excess of $2 million, (iii) the issuance or sale of any security having a preference on liquidation senior to common stock, or (iv) the sale by the Company of capital stock or warrants exercisable for its capital stock at a price below $0.03 per share.
Excess amount for incurring indebtedness			2,000,000
Exercise price of capital stock or warrant			$0.03
Preferred stock value				1,000,000
Fair value of warrants				2,995,791
Fair value of warrants recorded as charge to expenses		2,995,791
Subscription Agreement | Verify Me
Class of Stock [Line Items]
Beneficial conversion feature at fair market value	0	800,000		1,000,000
Subscription Agreement | Convertible Preferred Stock | Verify Me
Class of Stock [Line Items]
Number of preferred stock purchased				33,333,333
Preferred stock value in noncash transaction					366,667
Subscription Agreement | Common Stock | Verify Me
Class of Stock [Line Items]
Number of common stock called by warrants (in shares)				33,333,333
Value of shares issued				$1,000,000
Exercise price of warrants				$0.12
Shares of common stock shares issued on conversion					12,222,222
Subscription Agreement | Preferred Class
Class of Stock [Line Items]
Initial conversion price per share (in dollars per share)	$0.03		$0.03

FAIR_VALUE_OF_FINANCIAL_INSTRU2

FAIR VALUE OF FINANCIAL INSTRUMENTS - Liabilities measured at fair value on recurring basis (Detail) (Fair value on a recurring basis, USD $)	Dec. 31, 2014
Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability related to fair value of beneficial conversion feature	$0
Derivative liability related to fair value of warrants	6,370,709
Total	6,370,709
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability related to fair value of beneficial conversion feature	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability related to fair value of beneficial conversion feature	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability related to fair value of beneficial conversion feature	0
Derivative liability related to fair value of warrants	6,370,709
Total	$6,370,709

FAIR_VALUE_OF_FINANCIAL_INSTRU3

FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair value measurements within fair value hierarchy of derivative liabilities using Level 3 inputs (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at January 1, 2014	$6,000,000
Additional Warrants issued January 2014	444,000
Additional Warrants issued June 2014	34,222
Additional Warrants issued 3rd Quarter 2014	166,791
Additional Warrants Issued 4th Quarter 2014	4,903,900
Change in fair value of derivative liabilities	-5,178,204
Balance at December 31, 2014	$6,370,709

FAIR_VALUE_OF_FINANCIAL_INSTRU4

FAIR VALUE OF FINANCIAL INSTRUMENTS - Estimated fair value of embedded derivative liability using Black-Scholes (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Closing trade price of Common Stock	$0.02
Series A Preferred Stock Conversion price	$0.03
Intrinsic value of conversion option per share	$0

FAIR_VALUE_OF_FINANCIAL_INSTRU5

FAIR VALUE OF FINANCIAL INSTRUMENTS - Estimated fair value of warrants using Black-Scholes (Detail) (Warrant)	12 Months Ended
	Dec. 31, 2014
Fair Value, Option, Quantitative Disclosures [Line Items]
Annual Dividend Yield	0.00%
Minimum
Fair Value, Option, Quantitative Disclosures [Line Items]
Expected Life (Years)	3 years
Risk-free interest rate	1.10%
Expected volatility	174.80%
Maximum
Fair Value, Option, Quantitative Disclosures [Line Items]
Expected Life (Years)	4 years 8 months 9 days
Risk-free interest rate	1.65%
Expected volatility	203.60%

STOCKHOLDERS_EQUITY_Detail

STOCKHOLDERS' EQUITY (Detail) (USD $)	12 Months Ended		2 Months Ended	1 Months Ended	3 Months Ended		1 Months Ended	2 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Jun. 30, 2013	Jun. 30, 2014	Dec. 31, 2013	Jan. 31, 2013	Feb. 28, 2013	Feb. 01, 2013
							Warrant	Unit
							Unit	Warrant
Stockholders Equity Note [Line Items]
Worth of common stock to be paid	$400,000	$1,000,000
Research and development	10,590,271	655,840
Proceeds from exercise of stock options		17,919
Number of shares issued upon conversion of debt		1,890,000
Gains (Losses) on Extinguishment of Debt	-82,000	-1,221,875
Accredited Investor
Stockholders Equity Note [Line Items]
Stock option exercised share (in shares)			3,335,000
Proceeds from exercise of stock options			17,919
Number of common stock called by warrants (in shares)									1,000,000
Amount received for exercised of warrants									10,000
10% Senior Secured Convertible Promissory Notes
Stockholders Equity Note [Line Items]
Debt Conversion, Converted Instrument, Amount				1,628,000	216,249
Accrued interest of notes converted into common stock shares					208,339
Number of shares issued upon conversion of debt				7,400,000	8,448,519	7,900,000
Gains (Losses) on Extinguishment of Debt					-82,000
Private Placement
Stockholders Equity Note [Line Items]
Warrants exercise price (in dollars per share)							$0.12	$0.10
Sale of units under private offering, Issue price per unit (in dollars per unit)							0.045	0.05
Number of units sold under private offering (in units)							1,111,111	3,700,000
Number of units sold under private offering value							50,000	185,000
Number of share of common stock consist in each offering unit							1	1
Number of warrant consist in each offering unit							1	1
Patent And Technology Agreement
Stockholders Equity Note [Line Items]
Issuance of shares for services (in shares)	125,000,000
Warrants exercise price (in dollars per share)	$0.10
Number of common stock called by warrants (in shares)	125,000,000
Patent And Technology Agreement | Verify Me
Stockholders Equity Note [Line Items]
Issuance of shares for services (in shares)	6,349,206
Worth of common stock to be paid	400,000
Percentage of discount	10.00%
Closing price of share	$0.07
Closing price of share after discount	$0.06
Research and development	$400,000

STOCK_OPTIONS_Textuals_Detail

STOCK OPTIONS (Textuals) (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2000	Dec. 31, 2013	Dec. 17, 2003
Stock Option 2000 Plan | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized to grant options		1,500,000
Stock Option 2003 Plan | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized to grant options			20,000,000
Number of options available to be issued			1,274,004
Stock Option 2003 Plan | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized to grant options				18,000,000
Number of options available to be issued	14,774,004
Number of option issued	23,225,996

STOCK_OPTIONS_Textuals_1_Detai

STOCK OPTIONS (Textuals 1) (Detail) (USD $)	12 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended	3 Months Ended
	Dec. 31, 2013	Oct. 31, 2012	Dec. 31, 2014	Jun. 25, 2013	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amount received in funding	$235,000
Three year agreement | Vice Chairman of the Board
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation		200,000
Three year agreement | President and Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation		200,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price, description			The exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company). The aggregate fair market value (determined at the time of the grant) of stock for which an employee may exercise Incentive Stock Options under all plans of the company shall not exceed $1,000,000 per calendar year. If any employee shall have the right to exercise any options in excess of $100,000 during any calendar year, the options in excess of $100,000 shall be deemed to be Non-Statutory Stock Options, including prices, duration, transferability and limitations on exercise.
Stock options | Three year agreement | Common Stock | Vice Chairman of the Board
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued		19,000,000
Exercisable common stock share price		$0.05
Term for options		10 years
Expected volatility		146.10%
Risk-free interest rate		2.60%
Expected option life (in years)		10 years
Fair value of option issued expensed immediately		3,767,700
Method used to calculate the grant-date fair value of the warrants		Black-Scholes option pricing model
Percentage of number of options to purchase common stock		5.00%
Amount raised in funding				2,500,000
Stock options | Three year agreement | Common Stock | President and Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued		19,000,000
Exercisable common stock share price		$0.05
Term for options		10 years
Expected volatility		146.10%
Risk-free interest rate		2.60%
Expected option life (in years)		10 years
Fair value of option issued expensed immediately		3,767,700
Method used to calculate the grant-date fair value of the warrants		Black-Scholes option pricing model
Percentage of number of options to purchase common stock		5.00%
Amount received in funding				2,500,000
Stock options | January 22, 2013 | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued			1,000,000
Exercisable common stock share price			0.05
Term for options			10 years
Expected volatility			222.00%
Risk-free interest rate			1.90%
Expected option life (in years)			10 years
Fair value of options issued			99,972
Fair value of option issued expensed immediately			25,000
Method used to calculate the grant-date fair value of the warrants			Black-Scholes option pricing model
Allocated share-based compensation expense	12,600		26,500
Stock options | January 22, 2013 | Employee | Options Vests Immediately
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options vested			250,000
Stock options | January 22, 2013 | Employee | Option Vests One Year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options vested			250,000
Stock options | January 22, 2013 | Employee | Options Vested Year Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options vested			500,000
Stock options | February 25, 2013 | Employee
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued			500,000
Exercisable common stock share price			0.05
Term for options			10 years
Expected volatility			259.00%
Risk-free interest rate			1.90%
Expected option life (in years)			10 years
Fair value of options issued			89,998
Method used to calculate the grant-date fair value of the warrants			Black-Scholes option pricing model
Allocated share-based compensation expense					5,000
Stock based compensation reversed upon cancellation of stock options			5,000
Stock options | February 25, 2013 | Employee | Option Vests One Year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options vested			200,000
Stock options | February 25, 2013 | Employee | Options Vested Year Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options vested			200,000
Stock options | February 25, 2013 | Employee | Options Vested Year Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options vested			100,000
Stock options | March 13, 2013 | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued			2,000,000
Exercisable common stock share price			0.05
Term for options			10 years
Expected volatility			235.00%
Risk-free interest rate			2.00%
Expected option life (in years)			10 years
Fair value of options issued			439,963
Fair value of option issued expensed immediately			219,982
Method used to calculate the grant-date fair value of the warrants			Black-Scholes option pricing model
Allocated share-based compensation expense	55,447		43,394
Stock options | March 13, 2013 | Director | Options Vests Immediately
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of option vested			50.00%
Stock options | March 13, 2013 | Director | Vested on March 13, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of option vested			50.00%
Stock options | May 4, 2013 | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued			2,000,000
Exercisable common stock share price			0.05
Term for options			10 years
Expected volatility			235.00%
Risk-free interest rate			1.78%
Expected option life (in years)			10 years
Fair value of options issued			460,000
Fair value of option issued expensed immediately			230,000
Method used to calculate the grant-date fair value of the warrants			Black-Scholes option pricing model
Allocated share-based compensation expense	57,973		78,137
Stock options | May 4, 2013 | Director | Options Vests Immediately
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of option vested			50.00%
Stock options | May 4, 2013 | Director | Vested after the first year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of option vested			50.00%
Stock options | September 30, 2013 | Chief Operating Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued			1,000,000
Exercisable common stock share price			0.15
Term for options			10 years
Risk-free interest rate			1.39%
Expected option life (in years)			10 years
Fair value of options issued			99,840
Method used to calculate the grant-date fair value of the warrants			Black-Scholes option pricing model
Allocated share-based compensation expense	18,903		62,395
Stock options | September 30, 2013 | Chief Operating Officer | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility			268.40%
Stock options | September 30, 2013 | Chief Operating Officer | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility			272.80%
Stock options | September 30, 2013 | Chief Operating Officer | Option Vests One Year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of option vested			50.00%
Stock options | September 30, 2013 | Chief Operating Officer | Vested at the end of 24 months
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of option vested			50.00%
Stock options | December 2, 2013 | Chief Financial Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued			1,000,000
Exercisable common stock share price			0.15
Term for options			10 years
Expected volatility			266.10%
Risk-free interest rate			2.64%
Expected option life (in years)			10 years
Fair value of options issued			79,994
Method used to calculate the grant-date fair value of the warrants			Black-Scholes option pricing model
Allocated share-based compensation expense	15,123		49,916
Stock options | December 2, 2013 | Chief Financial Officer | Option Vests One Year
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of option vested			50.00%
Stock options | December 2, 2013 | Chief Financial Officer | Vested at the end of 24 months
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of option vested			50.00%
Stock options | March 28, 2014 | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued			6,000,000
Exercisable common stock share price			0.05
Term for options			10 years
Expected volatility			229.00%
Risk-free interest rate			2.73%
Expected option life (in years)			10 years
Fair value of option issued expensed immediately			599,893
Method used to calculate the grant-date fair value of the warrants			Black-Scholes option pricing model

STOCK_OPTIONS_NonEmployee_Stoc

STOCK OPTIONS - Non-Employee Stock Option/Warrant Activity (Detail) (Stock Options And Warrants, USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Option/Warrant Shares
Outstanding, beginning balance	111,516,665		82,807,221
Granted	10,349,209		38,144,444
Exercised			-9,435,000
Expired	-700,000
Outstanding, ending balance	121,165,874	[1]	111,516,665
Exercisable, December 31, 2014	121,165,874	[1]
Weighted Average Remaining Life, Exercisable, December 31, 2014 (years)	5 years 8 months 12 days
Exercise Price
Expired	$0		$0
Weighted Average Exercise Price
Outstanding, beginning balance	$0.09		$0.01
Granted	$0.01		$0.03
Exercised	$0		$0
Expired	$0		$0
Outstanding, ending balance	$0.10		$0.09
Exercisable, December 31, 2014	$0.10
Minimum
Exercise Price
Outstanding, beginning balance	$0.00		$0.00
Granted	$0.05		$0.10
Exercised			$0.00
Outstanding, ending balance	$0.01		$0.00
Exercisable, December 31, 2014	$0.01
Maximum
Exercise Price
Outstanding, beginning balance	$0.20		$0.20
Granted	$0.10		$0.15
Exercised			$0.07
Outstanding, ending balance	$0.20		$0.20
Exercisable, December 31, 2014	$0.20
[1]	Does not include 250,000,000 warrants that are due to be issued on January 1, 2015. The warrants has a fair value of $4,892,089 and are reflected in warrant liabilities on the balance sheet as of December 31, 2014 and the corresponding expense is reflected in research and development expense.

STOCK_OPTIONS_NonEmployee_Stoc1

STOCK OPTIONS - Non-Employee Stock Option/Warrant Activity (Parenthetical) (Detail) (Stock Options And Warrants, Patent And Technology Agreement, USD $)	12 Months Ended
Share data in Millions, unless otherwise specified	Dec. 31, 2014
Stock Options And Warrants | Patent And Technology Agreement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of warrants to be issued(in shares)	250
Warrant to be issued value	$4,892,089

STOCK_OPTIONS_Incentive_Stock_

STOCK OPTIONS - Incentive Stock Option Transactions (Details 1) (Detail) (Incentive Stock Options [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Remaining Life, Exercisable, December 31, 2014 (years)	8 years 3 months 18 days
Option/Warrant Shares
Outstanding, beginning balance	59,866,667	15,766,667
Granted	6,000,000	45,500,000
Exercised	-12,000,000	-900,000
Expired		-500,000
Outstanding, ending balance	53,866,667	59,866,667
Exercisable, December 31, 2014	51,366,667
Exercise Price
Granted	$0.05
Exercised	$0.05	$0.00
Expired		$0.05
Weighted Average Exercise Price
Outstanding, beginning balance	$0.06	$0.06
Granted	$0.01	$0.04
Exercised	$0.01
Expired	$0	$0
Outstanding, ending balance	$0.05	$0.06
Exercisable, December 31, 2014	$0.06
Minimum
Exercise Price
Outstanding, beginning balance		$0.00
Granted		$0.05
Outstanding, ending balance	$0.05	$0.00
Exercisable, December 31, 2014	$0.05
Maximum
Exercise Price
Outstanding, beginning balance		$0.10
Granted		$0.15
Outstanding, ending balance	$0.15	$0.15
Exercisable, December 31, 2014	$0.15

OPERATING_LEASES_Textuals_Deta

OPERATING LEASES (Textuals) (Detail) (General and administrative expense, USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
General and administrative expense
Operating Leased Assets [Line Items]
Total rent expense under leases	$65,950	$59,272

OPERATING_LEASES_Detail

OPERATING LEASES (Detail) (USD $)	Dec. 31, 2014
Leases, Operating [Abstract]
2015	$74,637
2016	31,605
Total	$106,242

RELATED_PARTY_TRANSACTIONS_Tex

RELATED PARTY TRANSACTIONS (Textuals) (Senior secured convertible notes payable, USD $) (Detail) (USD $)	12 Months Ended	3 Months Ended	1 Months Ended	3 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Jun. 30, 2013	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2012
						Shareholder
Related Party Transaction [Line Items]
Convertible notes payable					$114,000
Common stock shares issued on conversion of debt (in shares)	1,890,000
Common Stock
Related Party Transaction [Line Items]
Common stock shares issued on conversion of debt (in shares)	18,275	25,974,697
10% Senior Secured Convertible Promissory Notes
Related Party Transaction [Line Items]
Number of shareholders	5	5
Convertible notes payable	330,249	330,249
Amount of accrued interest owed by shareholders	300,677	300,677
Common stock shares issued on conversion of debt (in shares)		7,900,000	7,400,000	8,448,519
10% Senior Secured Convertible Promissory Notes | 2 Shareholders
Related Party Transaction [Line Items]
Number of shareholders					2
Convertible notes payable					114,000
Amount of accrued interest owed by shareholders					112,505
10% Senior Secured Convertible Promissory Notes | 3 Shareholders
Related Party Transaction [Line Items]
Number of shareholders					3
Convertible notes payable					323,000
Amount of accrued interest owed by shareholders					31,845
Convertible Notes Payable [Member]
Related Party Transaction [Line Items]
Number of shareholders						1
Convertible notes payable						140,000
Amount of accrued interest owed by shareholders	87,150	87,150
Common stock shares issued on conversion of debt (in shares)		12,375,000

SUBSEQUENT_EVENTS_Textuals_Det

SUBSEQUENT EVENTS (Textuals) (Detail) (USD $)	12 Months Ended	0 Months Ended
	Dec. 31, 2014	Mar. 27, 2015	Feb. 10, 2015
Subsequent Event [Line Items]
Proceeds from issuance of notes payable	$798,000
Notes Payable | Director | Subsequent Event
Subsequent Event [Line Items]
Proceeds from issuance of notes payable		$111,102	$25,000
Interest rate, notes payable		8.00%	5.00%
Note due date		25-Jun-15	10-Jun-15